

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 7/06, A61K 7/00, A61K 7/48, A61K 35/78	A1	(11) International Publication Number: WO 00/01351 (43) International Publication Date: 13 January 2000 (13.01.2000)
(21) International Application Number: PCT/US99/15297 (22) International Filing Date: 07 July 1999 (07.07.1999) (30) Priority Data: 60/091,910 07 July 1998 (07.07.1998) US (60) Parent Application or Grant TRANSDERMAL TECHNOLOGIES, INC. [/]; (). KIRBY, Kenneth, B. [/]; (). PETTERSSON, Berno [/]; (). KIRBY, Kenneth, B. [/]; (). PETTERSSON, Berno [/]; (). STEINBERG, Richard, A. ; ().		Published <i>= 6,444,234</i> <i>CLA + caffeine or</i> <i>topical</i> <i>for cellulite</i> <i>102 (a)</i> <i>cl 11-13, 15-18, 20-23,</i> <i>25-28</i>
(54) Title: COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF (54) Titre: COMPOSITIONS D'ADMINISTRATION TRANSDERMIQUE RAPIDE ET NON IRRITANTE D'AGENTS PHARMACEUTIQUES ACTIFS ET METHODES POUR LA FORMULATION DE CES COMPOSITIONS ET LEUR ADMINISTRATION		
(57) Abstract <p>Pharmaceutical compositions for the transdermal administration of a medicament or other active agent by topical application of the composition to the skin of humans or other animals are described. Methodology for formulating such compositions which provide for very rapid uptake of the medicament and transmigration into and through the skin to either fatty tissues or the vascular system, while minimizing irritation to the skin and/or immunological response, is based on a transdermal delivery system (TDS) wherein the medicament is modified to form a true solution in a complex formed from particular solvents and solvent and solute modifiers in combination with skin stabilizers. Uptake of the medicament is further facilitated and made more rapid by including Forskolin or other source of cellular energy, namely induction of cAMP or cGMP. Selection of specific solvents and solvent and solute modifiers and other functional ingredients and the amounts thereof are chosen such that there is a balance between the sum of the mole-moments [(molar amount of each individual ingredient) X (dipole moment of that ingredient)] of the delivery system and the sum of the molar moments of the composition in which the medicament is dissolved. Preferably, the van der Waals forces of the delivery system is also similarly matched to the van der Waals forces of the total composition, namely, delivery system plus active agent.</p>		
(57) Abrégé <p>L'invention concerne des compositions pharmaceutiques d'administration transdermique d'un médicament ou autre agent actif par application locale de la composition sur la peau de sujets humains ou animaux. La méthodologie de formulation de ces compositions assurant une absorption très rapide du médicament et une transmigration dans et à travers la peau, soit vers les tissus adipeux soit vers le système vasculaire, tout en réduisant au minimum l'irritation de la peau et/ou les réponses immunologiques, est basée sur un système d'administration transdermique (SAT) dans lequel le médicament est modifié pour former une solution vraie dans un complexe constitué de solvants et de modificateurs de solvants et de solutés particuliers en combinaison avec des stabilisants de la peau. L'absorption du médicament est facilitée davantage et rendue plus rapide par l'addition de Forskolin ou d'une autre source d'énergie cellulaire, à savoir l'induction de AMPc ou GMPc. La sélection de solvants et de modificateurs de solvants et de solutés spécifiques ainsi que d'autres ingrédients fonctionnels et de leurs doses est définie de manière à obtenir un équilibre entre la somme moles-moments [(quantité molaire de chaque ingrédient individuel) X (moment dipolaire de cet ingrédient)] du système d'administration et la somme des moments molaires de la composition dans laquelle le médicament est dissous. De préférence, les forces de Van der Waals du système d'administration sont aussi adaptées de façon similaire aux forces de Van der Waals de la composition totale, c'est-à-dire, le système d'administration plus l'agent actif.</p>		

no salt,
no Va

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/06, 35/78, 7/48, 7/00	A1	(11) International Publication Number: WO 00/01351 (43) International Publication Date: 13 January 2000 (13.01.00)
(21) International Application Number: PCT/US99/15297 (22) International Filing Date: 7 July 1999 (07.07.99) (30) Priority Data: 60/091,910 7 July 1998 (07.07.98) US (71) Applicant (for all designated States except US): TRANSDERMAL TECHNOLOGIES, INC. [US/US]; 1368 N. Killian Drive, North Palm Beach, FL 33403 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KIRBY, Kenneth, B. [US/US]; 8631 Uranus Terrace, Lake Park, FL 33403 (US). PETERSSON, Bemo [US/US]; 1100 3rd Street, P.O. Box 467, Perry, GA 31069 (US). (74) Agent: STEINBERG, Richard, A.; Sherman & Shalloway, 413 North Washington Street, Alexandria, VA 22314 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF		
(57) Abstract <p>Pharmaceutical compositions for the transdermal administration of a medicament or other active agent by topical application of the composition to the skin of humans or other animals are described. Methodology for formulating such compositions which provide for very rapid uptake of the medicament and transmigration into and through the skin to either fatty tissues or the vascular system, while minimizing irritation to the skin and/or immunological response, is based on a transdermal delivery system (TDS) wherein the medicament is modified to form a true solution in a complex formed from particular solvents and solvent and solute modifiers in combination with skin stabilizers. Uptake of the medicament is further facilitated and made more rapid by including Forskolin or other source of cellular energy, namely induction of cAMP or cGMP. Selection of specific solvents and solvent and solute modifiers and other functional ingredients and the amounts thereof are chosen such that there is a balance between the sum of the mole-moments [(molar amount of each individual ingredient) X (dipole moment of that ingredient)] of the delivery system and the sum of the molar moments of the composition in which the medicament is dissolved. Preferably, the van der Waals forces of the delivery system is also similarly matched to the van der Waals forces of the total composition, namely, delivery system plus active agent.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
RJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Licchtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5
Compositions For Rapid and Non-Irritating Transdermal
Delivery Of Pharmaceutically Active Agents And Methods
For Formulating Such Compositions And Delivery Thereof

10 Field of Invention

15 This invention relates to transdermal delivery of active
agents, including pharmaceuticals, cosmetics, nutrients, and
the like, across the skin barrier of humans or other animals
and to a method for developing new transdermal delivery
5 systems for any particular polar or non-polar active agent of
small or large molecular size, which delivery systems are
capable of rapidly delivering the active agent to a targeted
20 location systemically or locally.

Background of the Invention

10 The pharmaceutical industry is actively seeking to
develop new and improved modes of drug delivery to enhance the
effectiveness of particular drugs, including, targeting the
25 drug to the intended site, reducing dosage, decreasing
toxicity, and the like. Major efforts are underway in
molecule stabilization for parenteral applications, extended
30 release modalities for enteral drugs and photoactivated
chemotherapeutic molecules, for example. Delivery of
medications via transdermal drug delivery (TDD) systems
(patches) has also seen dramatic developments. For example,
35 20 it is now generally agreed that chemical modification of the
barrier properties of the skin is a safe and effective method
to enhance penetration of medicaments (Ref. 1). However, to
some extent it seems that this mode of delivery has reached
40 its technological limits.

25 The present inventors have analyzed the TDD systems and
have been able to identify certain limiting factors. These
include, for example, limitations to compounds which are

- 45 - lipophilic medicaments;
- medicaments with an effective therapeutic dose of ≤ 1

30 mg per day;

- 5 - medicaments having a melting point below about 150°C;
 - medicaments having a molecular weight of from less than
 about 300 to about 500 Daltons (the larger the molecule, the
10 less is the amount deliverable via the stratum corneum);
5 - molecules which do not elicit a rapidly cascading
 immune response when transmigrating the skin.

 With regard to the molecular weight limitation, currently
15 commercially available TDD systems deliver molecules with
 molecular weights less than about 340D and in amounts
10 generally less than about 1.0 mg per 24 hours.

 Additionally, candidate medicaments should also,
20 preferably, be soluble in ethanol and/or isopropanol and/or
 glycols or dimethyl sulfoxide (DMSO) and should not be
 chemically altered by solubilization. Another potentially
15 limiting factor is for compounds which can have efficacy at
 relatively small doses introduced systemically via the
25 capillary net of the dermis. Main limiting factors thus
 include molecule size and irritation potential of the
 medicament plus solvent(s) and other components.

20 The inventors have also analyzed the chemistry and
30 chemical structures of active ingredients and carriers of
 transdermal delivery systems and have found other limiting
 factors leading to the limited success of transdermal drug
 delivery. Most typically it has been observed that these
35 25 systems have not been widely acceptable because the drug
 carriers chemically bond with the medicament resulting in
 non-bioavailable compounds transmigrating the skin; or/and
 the carrier, e.g., DMSO, reduces the medicament yielding a
40 non-bioavailable or non-bio-equivalent compound or creates
30 toxic by-products of transmigration.

 Only about 1% or less of known medicaments would not be
45 excluded for administration by a TDD system based on the above
 limiting factors. Still further, TDD systems currently
 available are usually subject to broadly varying results as a
35 function of the circulation efficiency of the patient. Age,
 size and weight of the patient all impact how efficiently
50

these systems perform. For most TDD systems there is virtually no drug penetration for the first hour after application and often 24 to 48 hours are required to achieve a therapeutic level.

The anatomy and physiology of the integument was analyzed to understand the complex protective mechanism of physical, biochemical and bio-electrical gradients which work to minimize the penetration of foreign substances and sensitize the organism to react more rapidly and aggressively to future exposures. As a result of this analysis it is postulated that:

- The primary pathway of transdermally delivered drugs is paracellular, i.e., around the cells, then through the elastin glue.

- The glue-like compound, elastin, composed of collagen and hyaluronic acid and other lipids, which occupies the interstices between the cells of the top-most layer of the skin (i.e., the epidermis, including, e.g., stratum corneum (SC), lucidum, granulosum, spinosum) must be dissolved (or otherwise disrupted) in order for a medicament or other active agent, dissolved in a solvent, to transmigrate through viable skin (VS) to the subcutaneous tissues where the cutaneous plexi of the capillary net can be reached and/or deeper penetration achieved (Ref. 2). When the elastin is dissolved, other agents may then transmigrate the outer layers, so the body immediately begins to attempt to repair the damage caused by the dissolution.

- Skin penetration enhancers (SPE) which delipidize can reduce the barrier capacity of the SC as a function of species of enhancer and its concentration. Permeability may often be adjusted by modifying the HLB of the enhancer (Ref. 3).

- Capillary circulation acts as a sink for the medicament, thus maintaining a steep chemical potential gradient across the skin (Ref. 4).

- Diffusivity of a drug molecule is dependent on properties of both the medicament and the medium (carrier). The diffusivity in liquid media, in general, tends to decrease with increased molecular volume (Ref. 5).

- The rate of skin penetration is a function of (1) the Diffusion Coefficient, (2) the barrier partitioning tendencies, (3) binding affinities, and (4) the rate of metabolism of the medicament by the skin (Ref. 6). The Diffusion Coefficient of the medicament is influenced by (1) molecular weight, (2) molecular structure, (3) additives, (4) rate of metabolism of the medicament by the skin. Diffusion is also dependent on the carrier, with diffusivity decreasing with increased molecular volume.

- An optimum HLB is required for a medicament to penetrate efficiently. The optimum HLB may be predicted by plotting the log (Permeability Coefficient) vs. log (Oil and Water Partition Coefficient) of the medicament for the SC and the VS (Ref. 4).

- Highly lipophilic drugs bind readily in the VS and, therefore, dissolution into the blood is minimal (Ref. 6). Therefore, highly lipophilic drugs must be shielded to inhibit such binding.

- Skin metabolizes drugs effectively, so metabolism issues in the skin, such as, enzyme saturation and/or inhibition, medicament/metabolite fluxes (e.g., how rapidly and completely does the drug metabolize to a different form) should be taken into account.

- Un-ionized species of medicaments transmigrate more readily (Ref. 4). Generally, un-ionized species are two orders of magnitude more permeable than their ionized form.

- The Hildebrand Solubility Parameter (HSP) is useful for predicting the mutual solubility and compatibility of medicaments, SPEs, and polymers and for optimizing skin permeability (Ref. 7). The HSP describes the attractive forces between molecules and is defined as the square root of the Cohesive Energy Density (Ref. 8). The HSP spans a range where the low value is associated with lipophilic compounds

5

10

15

10

20

15

25

30

35

40

30

45

35

50

55

and a high value with hydrophilic compounds. The solubility parameter can be further partitioned into polar, non-polar, dispersive, and hydrogen bonding components which are useful to predict molecular interactions between compounds (Ref. 9).

The solubility parameter or Cohesive Energy Density is synonymous with lipophilic/hydrophilic properties (Ref. 4). Dipole moment is also an expression of the Cohesive Energy Density.

- Transient increases in cutaneous blood flows may result in increased systemic absorption of the drug from the depot of the TDD (Ref. 5).

Furthermore, cellular biological issues were reviewed in order to identify and categorize membrane and organelle functions, both in the integument and in other tissues, which might be subject to variations which might help or hinder tissue transmigration of a medicament and solvent. In particular, it is proposed that,

- SPE's and solvent modification systems can cause irritation apart from the medicament they are delivering.

Chronic exposure to irritants has the potential to become carcinogenic and, therefore, care must be taken in the design and testing of TDD systems.

- Efferent tactile corpuscles of nerves form an "early warning detection system." The cellular and humoral components of this peripheral immune surveillance system present in the skin are responsible for the genesis of a hapten-specific, cell-mediated immune response following the penetration of the skin by, and complexing of skin components with, sensitizing chemicals and drugs (Ref. 10). If a drug is able to penetrate the skin and covalently bind with amino acids in the skin, dermal hypersensitivity is possible. If the hapten-protein conjugate is of sufficient size to be recognized as a foreign antigen, a specific antibody or cell-mediated immune response will ensue that sensitizes the skin's immune system to the hapten molecule. Upon re-exposure of the skin to the sensitizing chemical, a dermal hypersensitivity reaction of the delayed onset type 4

hypersensitization may be elicited (Ref. 11). Effective transmigration must be able to elude or minimize this response to effectuate repeated challenge without anaphylaxis or ACD sensitization. Avoiding binding in the skin is, therefore, an important objective.

- Some SPE's reduce residence time of the medicament in the skin and reduce the extent of cutaneous metabolism thereby reducing exposure to the medicament or metabolite. The faster the medicament moves, the less metabolism takes place. Rate and extent of metabolism in the liver and skin on a unit basis are virtually the same and disposition is the same by IV dosage (Ref. 12).

- Virtually any solvent used to dissolve and form a medium for drugs is toxic on the cellular level at the concentrations required, therefore, the tissues are effectively challenged with eliminating the medicament and the solvent, thereby draining substantial energy from the system.

- Most challenges force the cell to expend adenosine triphosphate (ATP) to move compounds across gradients or to maintain barrier integrity against transmigration by compounds.

- Adenylate cyclase substrate for the cAMP system, when varied, can yield substantial changes in a cell's tolerance for, and ability to recover from, the challenge of dermal transmigration, accelerating the time line to a steady, bioavailable equilibrium of the medicament (Ref. 13).

Topical, transdermal drug delivery modalities, nevertheless, have certain apparent benefits so that there is still much activity not only in the patch systems but also in the non-patch transdermal delivery systems, such as gels, ointments, and other topical formulations.

OBJECTS OF THE INVENTION

Accordingly, it is a primary object of the invention to provide compositions for the rapid transdermal administration of medicaments or other active agents to humans or other animals which does not require use of a "patch" delivery system.

Another object of the invention is to provide compositions effective for transdermal delivery of active compounds not previously amenable to this route of administration, particularly for pharmacological agents having molecular weights in excess of about 300 D and/or at dosages in excess of 0.25 mg/cm² per day, especially, in excess of about 1 mg/cm²/day.

It is another object of the invention to provide topical compositions for transdermal delivery of active agents for humans and other animals which leaves the barrier properties of the skin substantially intact and which invokes only minimal or substantially no immune response at the site of application.

Still another object of the invention is to provide a standardized solvent/carrier base system which is useful for forming topically applied compositions for transdermal administration of many different medicaments with none or only minimal modification required to achieve a true solution of the medicament and effective, safe, and rapid transmigration of the medicament through intact skin.

Another object of the invention is to provide safe and effective compositions for transdermal administration of a variety of medicaments and other active agents of low or high molecular weight which allows repetitive applications over short or long periods of time at the same site on the intact skin without causing damage to or immunological reaction by the skin.

It is another object of the invention to provide a method for formulating safe and effective compositions for topical transdermal application of an active agent by matching the solvent/carrier system for the particular active agent which will allow the agent to transmigrate across the skin barrier with no or only minimal immunological response at the site of application and without degrading the chemical structure or bioactivity of the active agent.

5 These and other objects of the invention will become
clearer upon review of the following more detailed description
and specific embodiments, and with the aid of the accompanying
10 drawings in which:

5 BRIEF DESCRIPTION OF THE DRAWINGS

15 Fig. 1 is a graphical representation of the results
obtained in Example 13, for the flux ($\mu\text{g}/\text{cm}^2$) vs. time (h), of
morphine (as morphine sulfate) under open (lotion) conditions
using the topical delivery system SDS-L;

20 Fig. 2 is a graphical representation similar to Fig. 1
but for testing under closed (patch) conditions using the
SDS-L delivery system described in Example 13;

25 Fig. 3 is a graphical representation similar to Fig. 1
but using the topical delivery system SDS-S, as described in
15 Example 13;

25 Fig. 4 is a graphical representation similar to Fig. 2
(closed patch application) for transdermal delivery of
morphine, but using the topical delivery system SDS-S.

SUMMARY OF THE INVENTION

30 Based on the above observations and reviews of the
overall biological systems of the skin and vascular organs,
including at the cellular and microbiological levels, it was
concluded that an effective and "universal" transdermal drug
delivery system (as used herein, unless the context indicates
35 25 otherwise, the reference to "drug" delivery is intended to
include not only drugs, medicines, pharmacologicals, and other
biologically active ingredients, but also other active agents,
such as, cosmetically active substances, nutrient substances
and the like) should have the following characteristics and
40 30 features:

- ability to dissolve and emulsify the active agent down
to individual molecules (true solutions) in a carrier which
45 remains liquid long enough to penetrate the epidermis;
- remains stable as formulated and not form an
35 irreversible complex with other substances;

5 - does not damage the skin with repeated use;
 - releases the active agent appropriately and does not
10 alter the agent or leave as residual compounds which might be
 sensitizing.

10 5 The present invention provides a topical formulation for
 the transdermal delivery of an active agent which addresses
 the design of the integument as a biologically responsive
15 physical, chemical and bioelectrical barrier against the
 active agent(s) and solvent(s). Accordingly, solvent(s) and
20 10 modifying component(s) are selected so that permanent or
 strong covalent bonds with the medicament or other active
 agent are not formed, while the complexes that are formed
25 20 facilitate movement of the complex past the viable skin to its
 optimal targeted internal circulation system of blood, lymph
30 15 or neural, or beyond these systems, wherein the complexers and
 modifiers are readily stripped from the active agent at the
35 25 intended site of application, thereby leaving the active agent
 free to seek the appropriate receptors once released.

 At the same time, the formulations according to this
20 20 invention are designed to modify the active agent and
30 30 solvent(s) to minimize their reactivity and sensitizing
 characteristics as well as making the active agent more
 "slippery" thereby facilitating transmigration through the
35 35 skin. By facilitating the transmigration and increasing the
 rate of diffusion of the active agent and other system
40 40 components through the skin the less time the formulation will
 have to remain in the tissues and the lower the physiological
45 45 response. In part, this is accomplished by selecting
 solvent(s) and modifier(s) to provide a true solution, namely
50 50 a solution of the various components in the solvent system on
 a molecular level, while at the same time forming a protective
 "coating" or temporary complex with the active agent to
 facilitate its intact transmigration through the skin.

 The present invention also provides transdermal drug
35 35 delivery systems which may include a substance which can
 assist the skin in repairing damage which is caused by the
50 50 transmigration of the delivery system.

5 In one broad aspect of the invention there is provided a
topical formulation for rapid transdermal delivery of an
active agent through intact skin wherein the formulation
10 includes (1) active agent, (2) solvent system in which the
5 active agent is soluble, and (3) a substance capable of
in vivo stimulation of adenosine 3',5'-cyclic monophosphate
(cAMP) or cyclic guanosine 3',5'-monophosphate (cGMP).

15 The substance capable of in vivo cAMP stimulation is,
preferably, an extract of *Coleus Forskholi*, especially a
10 labdane diterpene, such as Forskolin, or colforsin or
coleonol.

20 The formulation may and, preferably will, also include
one or more additional ingredients effective for enhancing
percutaneous absorption of the active agent in its intact,
15 bioactive form. Such additional agents include, for example,
one or more of modifiers for the active agent (solute) and/or
25 solvents, such as, methylsulfonylmethane, terpene compounds,
skin penetration enhancers, glycerylmonolaurate, quaternium
cationic surfactants, N,N-dialkyl alkanolamines, such as N,N-
20 diethylethanolamine, steroids, such as dehydroepiandrosterone,
oily substances, such as eicosapentanoic acid, vitamins, such
30 as A, D₃, E, K₁.

According to a particular embodiment of the invention the
topical, liquid, composition is effective for transdermal
35 25 delivery of high molecular weight active agent (solute),
especially medicaments and other active agents having
molecular weights of at least about 350 Daltons (350D), at
delivery rates of greater than about 0.25 milligrams (mg) per
40 square centimeter (cm²) per 24 hours. According to this
30 embodiment, the composition may be formulated as a unit dosage
(e.g. one cubic centimeter (1cc)) containing from about 0.25
to about 1.5 mg of active agent having a molecular weight of
45 at least about 350D in a carrier in which the active agent is
completely dissolved. The carrier includes a solvent system
35 in which the active agent is at least substantially soluble,
at least one solvent modifying compound to facilitate
50 transdermal delivery of the active agent and, as necessary, to

5 increase solubility of active agent in the solvent system; and
at least one solute (active agent) modifying compound forming
a non-covalently bonded complex with the solute. In this
embodiment, too, addition of a substance, e.g., Forskolin, for
10 stimulating cAMP production, or substance for stimulating cGMP
production, is preferred for its ability to increase the rate
of percutaneous absorption of the active agent into and
through the stratum corneum (sc) and viable skin (vs).

15 In one particular aspect the present invention provides a
topical formulation for the transdermal delivery of an active
agent having a given polarity and dipole moment; the
formulation includes:

20 (A) at least one solvent in which the active agent is
soluble or is modified to solubilize the active agent, and
15 which has substantially the same dipole moment as that of the
combination of active agent plus solvent system;

25 (B) at least one solvent modifier having common
structural features as that of the active agent and comprising
an ethylenically unsaturated polar group containing at least
20 one functional group containing at least one heteroatom
selected from the group consisting of oxygen, nitrogen and
30 sulfur;

(C) at least one metabolizable solute modifier
comprising a compound capable of forming a temporary (non-
35 25 covalently bonded) complex with the active agent;

(D) at least one source of cellular activation energy;
and, optionally,

40 (E) at least one skin stabilizer for stimulating the
body's repair mechanisms in response to transdermal migration
30 of the active agent through the skin.

The present invention also provides, in a specific
embodiment, a topical formulation for the transdermal delivery
45 of a medicament (or other active agent) having a given
polarity, the formulation including

35 (a) at least one non-aqueous non-toxic solvent selected
from the group consisting of lower aliphatic mono- and poly-
50 hydroxy compounds;

(b) limonene or lemon oil;

(c) methylsulfonylmethane;

(d) skin stabilizer comprising at least one compound selected from the group consisting of aliphatic carboxylic acid having from about 8 to about 32 carbon atoms, an ester of said aliphatic carboxylic acid with an aliphatic alcohol having from 1 to about 20 carbon atoms, wherein said ester has a total of from about 9 to about 36 carbon atoms, Vitamin D₃, and mixtures thereof;

(e) solute modifier comprising at least one compound selected from the group consisting of 3,3'-thiodipropionic acid, ester thereof, salt thereof, oxindole alkaloid, polyphenolic flavonoid, sugar adduct of a gluconuride, isoflavones, phosphatidyl serine, phosphatidyl choline, vitamin D₃ and Vitamin K₁,

(f) at least one substance which induces *in situ* generation of cAMP or cGMP.

In accordance with a particularly preferred embodiment of this aspect of the invention the component (f) is, or comprises, forskolin or Colforsin, especially forskolin.

According to still another aspect of the invention there is provided a method for forming a composition for the topical application to the skin of a human or other animal for the transdermal delivery of an active agent of known or predetermined polarity contained in the composition. The method includes the steps of

selecting a solvent in which the active agent is at least substantially soluble;

selecting modifying agents for each of the solvent and active agent such that when the active agent is dissolved in a solvent system comprising solvent and modifying agents there will form a complex of at least one modifying agent weakly associated with the active agent through van der Waals forces and/or hydrogen bond affinities; said modifying agents comprising at least one ethylenically unsaturated compound having a polar group and an oxygen, nitrogen and/or sulfur containing functional group, and at least one compound for

balancing at least one molecular property characteristic of the solvent system and active agent, said molecular property characteristic being at least one of electrostatic energy, non-bonded energy, polarisability and hydrophobic bonding, and the polarities of the modifying agents are such that the dipole moment of the active agent closely matches the dipole moment of the active agent plus solvent system, and

forming the pharmaceutical composition by mixing each of the active agent, solvent and modifying agents.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

The present invention provides a transdermal delivery system which is able to quickly introduce a medicament or other active agent through intact skin or mucous membrane or other viable membrane or external covering of animal, including human, or plant, while minimizing damage and, therefore, minimizing the immune response of the skin or membrane to this introduction/challenge.

While the foregoing and following descriptions are given with respect to transdermal or percutaneous administration of drugs or other classes of active agent through human or animal skin, the principles and compositions disclosed herein are not so limited but will also be generally applicable to administration of a broad spectrum of active agents, including medicines, drugs, pharmacologicals and non-bioactive substances or agricultural chemicals for treating plants, and other viable animal membranes. In this regard, it will also be appreciated by those skilled in the art that certain substances may exert medicinal or pharmacological activity when used at high concentration while at lower concentration and/or for a lower extent of transmigration, e.g., without substantially reaching beyond the viable skin to the vascular or capillary network, will exert only a cosmetic effect or weaker pharmacological activity. It will also be appreciated that certain compounds, for example, quaternary ammonium

5 compounds, may in some cases constitute an active ingredi nt
while in other cases such compounds may be included as
modifying agents, skin stabilizing agent or for other
functional effect.

10 Accordingly, the term "active ingredient" or "active
agent" or similar term is intended to refer to that ingredient
or ingredients in the formulation which is intended to and
expected to have a half-life of more than a few minutes (e.g.,
15 at least about 2, preferably at least about 5 minutes) after
introduction into the body and the only ingredient(s) included
to accomplish, in the case of a drug or other medicinal or
pharmacological agent, a therapeutic outcome,
20 pharmaceutically, or, in the case of an agricultural agent, an
equivalent therapeutic outcome, agriculturally.

15 Furthermore, unless the context indicates otherwise,
terms such as "transdermal" or "skin" should be construed to
also include penetration through the outer layer of various
plant forms, such as trees, flowering plants, cacti, and the
25 like, including, for example, stems, leaves, shoots and the
like.

30 Rapid introduction of the active agent enables:

- minimal immune response or anaphylaxis, and
- repetitive dosing over the same area of skin over a
short term or, if needed, for a longer course of therapy.

35 25 In order to accomplish the above and other objectives the
delivery system is designed to (1) create a transient
modification of those aspects of the solvents and solutes
which encounter or trigger the body's defense mechanisms
40 against dermal transmigration and, (2) minimize or offset any
damage done by dermal transmigration.

30 The transient modification (1) is manifested by the
formation of a complex between the solute (active agent) and
45 the solvent or solvents and modifying agents or modifiers for
the solvent(s) and/or the solute. These complexes are formed
35 as non-chemical true solutions of the solute in solvent
wherein the components of the complex are held together
50 through weak association, including van der Waals forces

5 and/or hydrogen bond affinities but, substantially no covalent
bonding. Furthermore, the carrier for the solute which
includes the solvent(s) and modifying agent(s), as will be
10 described below in further detail, is selected to have common
5 structural elements (e.g., physical and molecular orientation,
size, shape, etc. and which may be considered as the
"morphological" structure of the compound) which are similar
15 to and compatible with the structural elements (morphology) of
the solute (active agent) and otherwise exhibits an affinity
10 for the solute whereby the solute is attracted to and
associates with the carrier to form a 3-dimensional structure
which may be analogized to a Velcro-type mechanism. That is,
20 the carriers of the transdermal delivery system of this
invention are designed for each particular drug or other
15 medicament or active agent which allows the resulting complex
of active agent to pass through each of the different layers
25 of the skin's defenses with minimal or no irritation while
carrying the active agent in its intact, non-dissociated
state. As the complex passes through each layer or layers one
20 or more modifying agents of the complex may be stripped away
30 from the complex, usually by preferentially bonding or
reacting with a component or components of the skin
layer, but without reacting with or disassociating the active
agent. This mechanism thus allows the active agent to reach
35 25 and be absorbed by or react with its intended target, usually
absorption into the vascular or capillary network.

In practice, however, in view of the overall similarities
of common structural elements with and among large classes of
40 medicaments, it has been possible to design a standard or
30 stock solution which, with only minor modifications or fine
tuning, can be used for many different active agents.

The stock solution will generally include (A) solvent(s);
45 modifying agents including (B) solvent modifier(s); and (C)
metabolizable solute modifier(s); (D) source(s) of cellular
35 activation energy; and (E) skin stabilizer(s). Other optional
ingredients may also be included, for example, (F) capillary
50 dilator(s); (G) enzyme activator(s). The active agent is

5 mixed with the stock solution, further modified, as necessary,
to increase solubility and/or more closely match the molecular
properties of the stock solution plus active agent to that of
10 the active agent, taking into account one or more effects of
5 the molecular interactions of molecules in a liquid. Each of
these components will now be described in further detail.

It is understood that all ingredients used in the
compositions of this invention must, within the applied and
15 recommended dosages, be non-toxic and safe for human use.

10 Also, all amounts, parts and percentages in the following
description and appended claims are on a weight basis unless
otherwise noted.

20 (A) Solvents

The solvent is the principal component of the carrier for
15 the active agent and, preferably, is one in which the active
agent is soluble or at least substantially soluble or can be
25 made soluble or become more soluble, by addition of one or
more solvent modifying agents. As used herein, by
"substantially soluble" is meant that the minimum effective
20 dose of the active agent, generally at least about 0.25 mg,
30 preferably at least about 0.5 mg, especially preferably about
1 mg, or more, will dissolve in 1 cc of the solvent(s) or in 1
cc of a mixture of the solvent(s) with solvent modifying
agent(s). Suitable solvents may be selected from any of the
35 25 solvents normally used for medicaments, cosmetics, nutrients
or other active agent to be delivered transdermally.

Preferred solvents include lower alcohols of from about 2
to about 6 carbon atoms, preferably from 2 to 4 carbon atoms
40 and may be monoalcohols, such as, for example, ethanol,
30 isopropanol, sec-butanol, or polyols, such as, for example,
ethylene glycol, propylene glycol, butylene glycol, glycerol.
Mixtures of solvents may be used. Other solvents, such as
45 ketones, e.g., acetone, methylethyl ketone, ethers, e.g.,
ethylether, may also be used, in amounts which will be safe
35 and non-toxic in use.

5 While the solvent system is generally non-aqueous water
may be used for water soluble active agents and for those
drugs or other active agents which are stable in the presence
of and not denigrated by the presence of water. Water may
10 also be introduced as a component of one of the other
ingredients, for example, as an alcohol:water azeotrope, etc.
When water is present in the solvent it will usually
constitute less than about 50 percent, preferably less than
15 about 10 percent, especially, preferably, less than about 2
10 percent, by weight of the total solvent although more or less
may be used depending on the active agent and so long as the
objectives of the invention can be met. Furthermore, as will
20 become apparent by the examples to follow, the compositions of
this invention and utilizing the principles which will be
15 described in more detail, hereinafter, may also be formulated
as aqueous emulsions, including wherein the aqueous phase is
25 the major and continuous phase. Such aqueous emulsions,
as is the case with non-aqueous (usually less than about 5%,
especially less than about 2%, of water) solvent systems, will
20 be rapidly absorbed by and release the active agent or agents
30 in, typically, less than one minute.

Generally, the total amount of solvent(s) will be
selected to assure dissolution of the solute and other
additives and provide suitable product viscosity. Generally,
35 25 the amount of solvent(s) falling within the range of from
about 5 to about 90 percent, preferably from about 25 to about
75 percent, based on the total composition, may be used.

(B) Solvent Modifiers

40 A solvent modifier is selected to modify the polarity of
30 the solvent system to closely match that of the active
ingredient (solute). Therefore, solvent modifiers will
usually be polar compounds (form polar ions in solution) and
45 will usually contain a functional group containing oxygen,
sulfur or nitrogen in its molecule. Also, if the active agent
35 is unsaturated the solvent modifier will usually also contain
double bonds in the straight-chain or cyclic portion to match
50 the structure of the active agent. Most importantly, the

5 solvent modifier or mixture of solvent modifiers enables the
solvent system [solvent(s) and solvent modifier(s)] to form a
weak complex with the active agent, i.e., an association via
10 van der Waals forces and/or hydrogen bonding, thus yielding a
5 stable composition with a high solute/solvent ratio. As used
herein, "stable" is intended to have its normal and usual
meaning, namely, that the composition may be stored at room or
elevated temperature for one or more days, usually 30 or more
15 days, without undergoing phase separation. By "high
10 solute/solvent" ratio is meant at least 0.25 mg solute per
cubic centimeter of solvent (or solvent plus modifying agents)
and, more generally, often amounts of solute exceeding the
20 solubility of the solute in the solvent alone, or in each
solvent of a multi-solvent system.

15 As noted above, solvent modifiers may be individually (or
as a group) selected from substances having structural
25 elements in common with the active agent. However, it has
been found that for many bio-active compounds and other active
agents, a relatively small group of solvent modifiers
20 facilitate the dissolution of the active agent and formation
of the weak association which enable the complex of active
agent-modifier to pass the defenses of the skin with minimal
irritation without modification of the chemical structure or
30 stereoscopic configuration of the active agent.

35 25 Thus, particularly favorable results have been obtained
by using as the solvent modifier one or more of lemon oil
(or/and d-limonene), Vitamin E, Pro-Vitamin B, D-panthenol and
methylsulfonylmethane (MSM).

40 The amount of solvent modifier will be selected to result
30 in the desired solute/solvent ratio, and will depend on
various factors, including, for example, primarily, the
polarities, and polarizabilities, dipole moments, van der
45 Waals forces of each component, including the solvent, solvent
modifier and solute (active agent).

5 In this regard, in order to match the polarities, dipole
moments, of the solute to that of the solvent system the
amount of the individual components of the solvent system will
10 be selected such that the weighted (molar) average of the
5 dipole moments of the individual components will be
substantially the same as the dipole moment of the solute in
solution.

15 Generally, the suitable amount of solvent modifier(s) to
achieve the desired solute/solvent ratio will fall within the
10 range of from about 0.0001 to about 50%, preferably, from
about 0.1 to about 35%, more preferably, from about 0.1 to
about 5%, based on the total composition.

20 (C) Solute Modifiers

The solute modifier may be included in the formulation of
15 the topical delivery system where necessary to facilitate
dissolution of insoluble or sparingly soluble solutes at
25 higher concentrations. Solute modifiers which form reversible
or temporary complexes with the solute to facilitate passage
through the skin while minimizing immunological response are
20 especially effective. The solute modifier will also,
30 optimally, be a nutritional compound which will be metabolized
by the body once the solute is released from the complex.

Examples of preferred solute modifiers include, for
example, terpenes, such as, for example, *Uncaria Tomentosa*
35 25 ("Cat's Claw"), oxindolealkaloids, quercitrin (glycoside of
quercitin), genistein and its glucoside, genistin,
polyphenolic flavinoids, such as found in concentrated grape
seed extracts, scutellarein and other sugar adduct
40 gluconurides, such as, scutellarin, trans-ferulic acid,
30 alpha-lipolic acid, sterols, such as, for example, cholesterol
and cholesterol-like compounds and hormones, such as
isoflavones, 3,3'-thiodipropionic acid (sulfurated propionic
45 acid), phosphatidyl serine and choline, Vitamin D₃, Vitamin K₁,
dehydroepiandrosterone (DHEA). Still other suitable candidate

5 compounds include, for example, berberine, piper nigrum (e.g.,
Bioperin®), phosphatidyl serine, phosphatidyl choline.
Another group of candidate compounds include boswellic acid,
10 hypericum, phytic acid.

5 The selection of the particular complexer will facilitate
movement of the solute-complex past the stratum corneum and
viable skin to its optimal targeted internal circulation
system of blood, lymph or neural; or past the vascular system,
15 to anchor the bio-active agent, if so desired, deep in the
10 tissues.

The suitable amount of the solute modifier may be
determined based on such factors as, for example, solubility
20 of the modifier in the system (e.g. solvent plus solvent
modifiers), its molecular compatibility with the solute, its
15 ability to modify the polarizability of the solute to increase
the concentration (solubility) of solute in the solvent, etc.
25 Generally, the amount of solute modifier will be at least
about 0.003%, such as, for example, from about 0.003 to about
5%, preferably from about 0.1 to about 5%, especially
20 preferably from about 0.1 to about 4%, based on the weight of
30 total composition. Furthermore, it is especially preferred
that the amount of solute modifier or modifiers is equivalent
to the amount of solute to provide a 1:1 interaction between
modifier(s):solute.

35 25 In general, the above described modifying agents, i.e.,
solvent and solute modifiers, as well as other components of
the solvent/carrier delivery system of this invention should
preferably be selected from substances which the body
40 recognizes as usable building blocks of other physiological
30 systems. This selection therefore facilitates nearly complete
disassociation of the medicament from the delivery system once
in the body. Since these carrier/complex compounds are
45 reducible to elemental building blocks of physiology they
should do no harm to the body.

5 (D) Source of Cellular Activation Energy

 The process by which transdermal drug delivery operates
 involves moving molecules across chemical and electrical
10 gradients. Under ordinary tonic conditions, the introduction
 of materials through the skin results in chemical cascades
 that consume relatively large amounts of energy as the body
 seeks to defend itself against the challenge. Therefore, the
15 topical transdermal delivery system of the present invention,
 according to one preferred embodiment, includes a substance
20 which brings stored energy or the stimulus for release of
 stored energy on a cellular level, thereby minimizing energy-
 negative reactions, which could lead to sensitization, ACD or
 anaphylaxis. By including such stored energy substance, there
15 is a multiplied net increase in available cellular energy and,
 accordingly, the potential acceleration of those reactions
 which result in the active agent ultimately reaching its
25 target and being effectively utilized by the body.

 While the composition may be formulated to utilize
 adenosine diphosphate (ADP) or nicotinamide adenine
20 dinucleotide (reduced form) (NADH) or flavin adenine
 dinucleotide (reduced form) (FADH₂), such compounds tend to be
30 unstable and, therefore, are often not preferred.

 There has been identified a group of botanical compounds
 which, due, apparently, to so-called signalling mechanisms,
35 induce high concentrations of enzyme-substrate complexes to be
 formed, such as by activation of the N_q (stimulatory) protein
 of adenylate cyclase, thereby resulting in cellular levels of
 adenosine 3',5'-cyclic monophosphate (cAMP) approaching the
40 maximal limits of cellular cAMP concentration.

30 In particular, extracts of the plant *Coleus Forskohli*,
 and especially, Forskolin, a labdane diterpenoid, have been
 found to have a particular ability to stimulate the production
45 of cAMP in cells (Refs. 14 and 15). Other extracts of *Coleus*
 Forskohli, such as, Colforsin or coleonol, for example, may
35 also be used.

Other examples of activation energy sources for stimulating generation of cAMP, either via precursors or cellular activators, include, for example, methyl xanthines, Saikogenin and Saikosaponin, *Angelacie dahuricae radix* (yielding angelic acid), phelopterin, oxypeucedanin.

Examples of substances which stimulate cellular production of cGMP include acetylcholine, cytidene diphosphocholine and ascorbic acid (Vitamin C).

The amount of the activation energy source will depend on such factors as, for example, the mechanism of action of the active agent, energy of activation (positive or negative) when active agent encounters its intended receptor (to enhance or decrease cAMP or cGMP levels), etc. Generally, suitable amounts of forskolin or acetylcholine or other source of cellular activation energy, will fall within the range of from about 0.001 to about 0.1%, preferably, from about 0.001 to about 0.01%, more preferably, from about 0.001 to about 0.005%, based on total composition. As will be appreciated by those skilled in the art, cGMP is considered an antagonist for cAMP. cGMP stimulation will generally be appropriate for situations where it is desired to enhance immune function, such as lymphocyte mediated cytotoxicity, during infection, carcinogenesis, etc. Conversely, cAMP stimulation is generally appropriate in situations where immune system modulation is desired.

(E) Skin Stabilizers

Skin stabilizers may be included in the compositions of this invention to stabilize the skin prior to passage and to assist the skin to repair any damage resulting from the transmigration of the active agent and solvent and other components of the formulations.

Suitable skin stabilizers may provide one or more of the following attributes to facilitate safe and effective dosing of the active agent while avoiding local or systemic sensitization: form hydrogen bonds and complex with free radicals; act as a bridge for collagen, keeping the strand intact temporarily during repair; stimulate the body's repair

mechanisms, modulating prostaglandins, cytokines and the like; re-stabilize the Elastin complex after the composition passes through the skin; carry cationic potential, stimulating nerve transmission, i.e., decreasing nerve repolarization time at synapses. In addition, preferred skin stabilizers should be able to be metabolized by the body and should also shield the medicament or other active agent from the skin's defense mechanisms by forming suitable complexes which will be readily uncomplexed when the active agent reaches its intended site.

Examples of substances which may function as skin stabilizers and which may be included in the compositions of this invention include glycerin monolaurate (e.g., as Lauricidin®) and similar fatty acid esters, Vitamin D₃, alkoxy glycerols, unsaturated fatty acids, such as, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and gamma-linolenic acid (GLA), Vitamin E (alpha tocopherol) and the esters, e.g., acetate, and derivatives thereof, e.g., tocotrienol, D-panthenol, phytantriol, dehydroepiandrosterone (DHEA), pregnenolone, pregnenolone acetate, esculin, allantoin, ascorbyl palmitate, and the like.

Suitable amounts of the skin stabilizers may be determined based on such factors as, for example, type of, reaction between drug (active agent) and skin, between solvent and skin, etc. Generally, amounts of skin stabilizer, when present, will be at least about 0.01%, such as, for example, from about 0.05 to about 5%, preferably, from about 0.1 to about 5%, more preferably, from about 0.1 to about 2%, by weight, based on total composition. It is preferred to select stabilizers which will be effective in stabilizing the skin at as low a concentration as possible.

(F) Other Ingredients

(i). Membrane permeability modifiers.

In order to further enhance the ability of the solute to reach its cellular target the compositions of this invention may optionally include substances which have the ability to provide a transitory effect on membrane permeability. Many such substances are described in the general and patent

literature and are often referred to as skin penetration enhancers, percutaneous absorption enhancers and similar terms. For instance, the fatty acid esters, alkoxy glycerols, allantoin, ascorbyl palmitate, and unsaturated fatty acids mentioned above as skin stabilizers may also sometime be effective to temporarily enhance cell membrane permeability.

Other useful membrane permeability enhancers which have a transitory effect include, for example, Quaternium 28, Quaternium 18, and other cationic quaternary ammonium compound surfactants or emulsifiers, sulforaphen, cineol terpinen-4-ol, N,N'-diethyl ethanolamine, N,N'-dimethyl ethanolamine, and the like.

When used, amounts of the membrane permeability modifiers may range from about 0.01 to about 5%, preferably, from about 0.01 to about 4%, more preferably, from about 0.05 to about 2%, based on the weight of total composition.

(ii). Enzyme Activators/Signalling Compounds

Substances which function as signalling agents, namely, to provide a signal to the target cell or tissue but without crossing the cellular boundary either intact or as fragment but which facilitate the uptake of medicaments or other bio-active agents, such as by stimulating a particular intercellular response, may also be included in the subject compositions.

In particular, mention may be made of substances which modulate enzyme-substrate (ES) complexes to change the velocity of reactions and the resulting kinetic energy, such as, for example, the relative saturation of the enzyme by the substrate. In addition to the above mentioned functions, Forskolin, sulforaphen and sulforaphane are believed to function as such enzyme activators/signalling compounds, by acting as catalysts for the ES reaction, thereby yielding more rapid orientation of ES complexes to cellular receptors.

(see, e.g. Ref. 13, Chapter II, pages 235-253)

Suitable amounts of such enzyme activators/signalling compounds will usually be in the range of from about 0.01 to about 0.05%, preferably, from about 0.01 to about 0.02%, by weight, based on the total composition.

(iii). Capillary Dilators

Compounds which function as capillary dilators may also be included in the subject formulations to facilitate passage of the active agent-complex through the skin and/or provide additional capillary surface area to facilitate uptake of the active agent into the vascular system. Compounds which may be incorporated to function as capillary dilators should be of low toxicity and readily reversible; suitable compounds include, for example, in addition to known vasodilators, saponins, Quaternium 28, and sulforaphen. Preferred compounds should be able to sequentially open and close ("unzip/zip") the hydrogen bonds in hyaluronic acid (HA) of elastin as the complexed active agent passes through the skin.

Suitable amounts of capillary dilator, when present, may range from about 0.1 to about 2%, preferably, from about 0.1 to about 1.5%, by weight, based on the total composition.

Formulations

In formulating a carrier system of solvent, modifying agents, including solvent modifier and solute modifier, and other components, for the transdermal delivery system of this invention, several factors may be considered in selecting the particular ingredients to be included. For example, such factors as (1) the availability of pure drug versus a salt of the drug; (2) the solubility of the active agent (usually solubility of a solute in a solvent may be predicted by the relative dipole moments, the closer in value the more soluble will be the solute); (3) whether or not an ingredient will form an adduct or otherwise react with or degrade the solute or the complex of solute-solvent; (4) common structural features and physical characteristics of solute and solvent; (5) hydrophilic/lipophilic balance (for non-polar solutes); (6) pH (should be matched to that of the active agent, generally in the range of from about 2.5 to about 8.0,

5 preferably 3.0 to 6.0, especially from about 3 to 4,
especially for acidic active agents and/or to minimize or
relieve pain on the exposed skin where the composition is
10 applied; pH may be increased or decreased depending on the
5 active agent, e.g., to prevent ionization or salting out
effects; the compositions may often be formulated to be
self-buffering but, if necessary, pH may be adjusted by
15 addition of appropriate acids or bases, or by addition, for
example, of quaternary compounds, ethylene diamine tetraacetic
10 acid, or the like).

The topical transdermal delivery system of this invention
is preferably in the form of a lotion or similar free flowing
20 liquid (e.g., solution, emulsion, etc.). Due to the very
rapid absorption and uptake of the active agent the lotion may
15 be directly applied to the skin without accommodating for
product runoff. For example, in most cases the formulation is
25 rapidly absorbed into the skin within a few to several seconds
after application and with a high (e.g. >90%) percentage of
the active agent being transmigrated and made bio-available.

20 However, if desired, various additives, such as
thickeners or gelling agents may be incorporated to form gels
or creams according to standard pharmacological and cosmetic
technology. Alternatively, the topical transdermal
composition may also be incorporated into a TDD system, e.g.,
35 25 patch. However, in all of these modified forms it is expected
that the efficiency of delivery will be impaired with regard
to rate of absorption and amount of active agent delivered.
Therefore, it is generally preferred to exclude gelling or
40 thickening agents and to apply the formulation as a liquid
30 (lotion) directly to the skin rather than as a component of a
patch system or directly as a gel.

A standardized or Stock Delivery System (SDS) for the
45 solvent/carrier delivery system which has been found to be
effective for a wide range of drugs and other active agents is
35 set forth below. In the following table the "amount" of each
ingredient is on the basis of an approximately 2 liter system.
50 The amount of the active ingredient or ingredients which may

be incorporated into the SDS will depend on the nature of the active ingredient, but generally may range from about 0.1 gram to about 100 grams, preferably from about 0.1 to about 60 grams per liter of SDS, more preferably, at least about 0.25 gram, especially at least about 0.5 gram, such as from about 1 to about 45 grams or more, per liter of SDS, corresponding to a 1 cc unit dosage of from about 0.1 to 100 mg, preferably from about 0.1 to 60 mg, more preferably at least about 0.25 mg, especially at least about 0.5 mg, most especially at least about 1 mg, per cubic centimeter (cc). These ranges apply for both biological (e.g., drug) and non-biological (e.g., cosmetic) active ingredients.

	<u>Compound</u>	<u>Function</u>	<u>Amount</u>			<u>units</u>
			<u>broad</u>	<u>intermediate</u>	<u>specific</u>	
15	Ethanol, 1-propanol, or sec-butanol	solvent	1000-1200	1050-1150	1125	cc
25	Propylene glycol	solvent	700-900	750-850	800	cc
	Natural Lemon Oil	solvent modifier	1-3	1.5-2.5	2.0	g
	D-Panthenol	solvent modifier	0.5-1.5	0.7-1.2	1.0	g
20	Methyl sulfonyl methane	solvent modifier	1-3	1.5-2.5	2.0	g
30	Glycerol Monolaurate	skin desensitizer	2-10	3-8	5.0	g
	Vitamin D ₃	skin stabilizer	0.01-0.5	0.04-0.25	0.1	cc
	Uncaria Tormentosa	solute modifier	1-3	1.2-2.5	2.0	g
35	(15% polyphenols)					
25	(3% oxindoles)					
	3,3'-Thiodipropionic acid	solute modifier	0.5-2	0.7-1.6	1.0	g
40	Forskolin (pure) or	Source of ATP	0.01-1	0.02-0.6	0.1	g
	Forskolin (extract 40%)		0.1-2.5	0.1-1.4	1.0	g

5 The above Stock Delivery System may be modified, generally, as
a first approximation, as a function of the polarity of the
active agent. Where the solute is soluble in the
10 alcohol/glycol solvents at the desired level no further
5 solvent modification, as such, may be required. However, it
is often preferable in such case to modify the system to allow
even higher dissolved solute concentrations so that smaller
unit dose or less frequent applications are feasible.

15 In this regard, it is understood that the dipole moment
10 of a given compound may be taken directly from the literature,
when available, or otherwise measured or calculated by
standard techniques, including commercially available chemical
20 modeling software packages. Generally, dipole moment is
experimentally determined for an element or compound by
15 suspending a molecule in an electromagnetic field and
measuring the amount of energy (torque) to rotate the molecule
one rotation. Dipole moment is correlated to van der Waals
25 forces and the number of hydrogen bonds as well as
electrostatic energy of a molecule. Two chemical entities
20 with approximately the same dipole moment will usually have an
affinity for and be attracted to one another without the
30 necessity for covalent bonding.

To determine the dipole moment of the solvent(s) and
modifiers, a weighted average of the dipole moments of the
35 25 individual components is used. The weighted average should
closely approximate the dipole moment of the solute. The
closer the match the faster will be the rate of transmigration
through the skin. Generally, the Stock Delivery System will
40 be modified, as necessary, to move the dipole moment of the
30 solvent solution with modifying agents and other additives,
including the solute, to as close as possible to that of the
solute, preferably within 15%, especially within 10%, most
45 especially within 5%, of the dipole moment of the solute.

More specifically, in accordance with the preferred
35 method for forming the compositions of this invention,
especially for increasing the amount of drug or other active
50 ingredient which can be stably carried in solution in the

5 inventive transdermal delivery compositions, the selection of
and the amounts of the ingredients of the solvent system and
other functional additives may be determined, in the first
10 instance, by balancing the dipole moment of the active agent
5 relative to the dipole moment of the final composition. The
dipole moment of the final composition is taken to be the
weighted average dipole moments of each individual ingredient.
15 The weighted average is obtained by calculating the sum of the
mole-moments of each ingredient, where the mole-moment is
10 obtained by multiplying the amount, in moles, of an ingredient,
in a given volume, e.g., 100 cc, by the dipole moment for that
ingredient. For purpose of this calculation it is assumed
20 that each ingredient in the composition acts independently of
the other ingredients. Thus, for example, the dipole moment
15 of any particular ingredient does not take into account the
electronic, e.g., repulsive or attractive, effects of other
25 ingredients. However, by taking concentrations into
consideration, that is, by multiplying individual dipole
moments by molar concentrations, a reasonable approximation of
20 the matching of the system's properties with that of the
solute will generally be achieved.

As will be described further below, closer and more
accurate matching or fine-tuning of the solute and delivery
system may be achieved by taking other molecular
35 25 characteristics into consideration.

It is also understood that for the above Stock Delivery
System, the stated amounts may be varied, for example, by as
much as about $\pm 2.5\%$ or more, depending on the particular
40 active agent, and the desired degree of matching of dipole
30 moments, and/or, other molecular properties, particular van
der Waals forces, as discussed above and below. One or more
of the compounds listed above may be omitted or replaced by a
45 functionally equivalent compound. Some of the ingredients may
also provide functions in addition to those stated in the
35 table.

For example, glycerol monolaurate, commercially available under the tradename, Lauricidin®, may be replaced, in whole, or in part, by other long chain fatty acids or esters.

3,3'-Thiodipropionic acid is primarily effective to promote delivery of amino acids, glycosides and sugars and, for other types of active agents, may be omitted, or replaced with other propionic acid derivatives. Similarly, Uncaria Tormentosa (Cat's Claw) is primarily effective in delivery systems for primary alkaloid and terpenoid active agents, and may be replaced with similar terpenoids, oxindolealkaloids, polyphenolic flavinoids, etc. Vitamin D₃ also functions to sweep toxins and enhances Na/K and Mg/Ca pumps.

In addition to the above ingredients the Stock Delivery System may also include, for example, phytantriol which has a similar function to d-panthenol, namely, as a solvent modifier and for its ability to facilitate refraction from hyaluronic acid (HA) in skin. When added to the stock formulation its typical amount is about 1.0 g (per 2 liters).

Dehydroepiandrosterone (DHEA) is another highly useful solute modifier. When incorporated in or added to the SDS it is usually effective in amounts of about 100 mg (per 2 liters). Other optional, but often useful components which may be included in or added to the above SDS include, oily substances, for example, conjugated linoleic acid (CLA), medium chain (e.g. C₆-C₈) mono-, di-, or tri-glycerides, olive oil, Emu Oil, or Melaleuca Oil (preferably 100% purity) to increase the saturation point of the system but without facilitating supersaturation; N,N-diethylethanolamine or N,N-dimethylethanolamine, effective for modifying dipole moment and aiding in complexing of solute to modifiers, as well as a skin penetration enhancer; pregnenolone or pregnenolone acetate, as a drug complexer and/or for increasing transdermal migration and/or skin stabilization; transferulic acid or alpha lipolic acid, as anti-oxidants and

5 for controlling the re-complexing of the HA in elastin and
skin, also functioning as a solute complexer; Berberine, as a
10 signalling mechanism for enhancing more efficient uptake of
certain medicaments by cells.

5 It is understood that the above are only exemplary of
suitable additives and modifications to the transdermal
delivery systems of the invention and that other additions,
15 deletions or modifications can be made within the guidelines
provided herein and by the more detailed examples to follow.

10 While the Stock Delivery System as above or appropriately
modified for the particular active agent of interest will
usually be formulated in large size batches the compositions
20 of this invention including the active agent will often
preferably be provided for dispensing in unit dosage forms, as
15 well known in the art. For example, individual sealed
packages or metered dosage pump type containers for dosing
25 about 1cc of composition, may be provided to contain
sufficient active agent for a single application.

Laminar matrix transdermal systems are designed to leech
20 medicament through the stratum corneum into the dermis and the
30 vicinity of the cutaneous plexi of the capillaries. This is a
slow process, usually requiring hours to days to deliver the
maximum available dose. Since deep penetration is generally
35 not possible for these systems without external iontophoretic
25 accelerators, they are limited to delivery of medicaments
which are systemically efficacious in relatively small doses,
and generally only deliver one third of the drugs with which
they are loaded.

40 In contrast, the transdermal delivery system of this
30 invention can effectively delivery at least about 90% or more
of the medicament rapidly through the skin to the underlying
fatty tissue. This delivery may be accomplished in only a few
45 to several tens of seconds or just a few minutes or less. In
some cases, it may be desirable to slow down the rate of
35 trans-migration, for example, to direct the dose of the

5 medicament for systemic administration via the capillary net
of the dermis. Particular medicaments for which systemic
administration is often indicated include, for example,
10 hormones, vitamins, systemic antibiotics.

5 Such slowing down may be accomplished by modifying the
stock delivery system so that there is mismatching of the
dipole moments of the solute and the solvent(s) and modifying
agent(s), for example, at least about 15% or more difference,
15 such as about 15 to about 35% variation, especially from about
20 to 30% variation. By so varying the dipole moments and/or
other molecular characteristics, of the solute and the SDS for
the solute a more shallow penetration of the solute and/or a
20 less acute uptake curve may be achieved. Here too, however,
the resulting complex of the solute with the SDS components
15 will effectively shield the medicament (active agent, solute)
from the body's defenses, yet will not "slip" through quite as
25 effectively or efficiently. This dipole moment mismatching,
may therefore, be effectively utilized to insure that, at any
given time, more medicament is in the general vicinity of the
20 cutaneous plexi and available to be picked up by the capillary
network for systemic delivery.

In the case of therapy requiring slower delivery, the
system may be balanced to take longer to get to the strata of
the target, by emphasizing lipophilic binding affinities in
35 the solute modifiers. Some medicaments may safely be moved
25 past the cutaneous plexi and stored in the fascia beneath the
capillary net. This level is not as well defined by cell-
mediated immune response and may serve as a natural storage
40 and release matrix for delivery of these medicaments.

30 Slower transmigration and/or bioavailability may also
often be achieved, for example, by modifying the hydrophilic-
lipophilic balance (HLB) of solute modifiers and/or by
45 "shielding" the medicament with lipids which will increase the
time to de-complexing of the solute-modifying agent complex.

5 While the above discussion focuses on the matching of the
dipole moment of the active agent with the SDS, e.g.,
solvent(s), solvent modifier(s) and solute modifier(s), and
10 will allow one skilled in the art to effectively formulate
5 topical delivery systems according to the invention, still
further refinements, and improved consistency, may be obtained
by further taking into consideration other parameters which
are characteristic of the physicochemical properties of the
15 solute (active ingredient, e.g., drug) and the carrier
10 components of the topical delivery system. In particular, the
following properties of the solute and the delivery or carrier
system can be measured or calculated or may, in some cases be
20 obtained directly from the published literature: entropy,
enthalpy, Free energy, Potential energy, Kinetic Energy,
15 Dipole Moment, Surface Interaction parameters. Matching these
various parameters between the solute and the delivery system
25 will facilitate the transdermal delivery of the solute to the
intended target.

More particularly, the following is a more specific
20 overview of how the solvents, modifying agents and other
enhancing agents and additives may be compounded together to
30 standard stock delivery carrier system and how any particular
medicament molecule (or other active agent) is evaluated and
the delivery system consequently modified to maximize
35 25 solubility and optimize transmigration to the target level of
skin or tissue.

Many molecular properties come into play with molecules
in close proximity. A representative list of these includes
40 steric energy, heat of formation, dipole moment, charge
30 density, non-bonded energy, COSMO solvation in water,
electrostatic potential, electron spin density, hyperfine
coupling constants, atomic charges, polarisability and others
45 such as IR vibrational frequencies. According to the present
invention, the molecular evaluation system is particularly
35 concerned with 4 of the several forces in play on the
molecules of the system and the medicament. These four
50 elements are:

- Electrostatic Energy
- Non-bonded Energy
- Polarisability
- Hydrophobic Bonding

These four elements constitute a graded, increasingly fine approximation to balance of those factors and vectors which are predictive of dissolving a particular medicament in a liquid medium, the aggregation of which is designed to rapidly transmigrate the lipid domains of the SC by means of temporary disruption, continue traverse through the VS to the capillary plexi beneath or past the plexi into the fascia lata or deeper as required, the entire process being accomplished so as to assist in repair of damage secondary to domain modulation and minimization of hapten formation and any subsequent cascade.

Electrostatic Energy

The Electrostatic energy which is the first parameter of intermolecular forces which may be controlled can be described with the equation:

$$E_{\text{Electrostatic}} = \sum_i \sum_j \frac{q_i q_j}{D r_{ij}}$$

where the Electrostatic energy is a function of the charge on non-bonded atoms, q ; their inter-atomic distances, r_{ij} , and a molecular dielectric expression, D , which accounts for the attenuation of electrostatic interaction by the environment, e.g. between the solvent and solute modifiers and between the system and the medicament itself.

In a preferred embodiment, the electrostatic energy may be modelled by the Chem3D software, available from Cambridge Soft Corporation, Cambridge, Mass., using atomic charges for charged molecules and bond dipoles for neutral molecules. There are three interactions which are accounted for through the Chem3D software. These include Charge/Charge interactions; Dipole/Dipole interactions; and Dipole/Charge interactions. These interactions are calculated for each molecule of the carrier system and the medicament separately and then a weighted molar average calculation accounts for the

system as a whole, and this quotient is balanced against the medicament as to gross order of magnitude. Each type of interaction uses a different form as shown below:

Charge/charge contribution:

$$E = 332 \sum_i \sum_j \frac{q_i q_j}{D_q r_{ij}}$$

where the value 332 converts the results to units of kcal/mole.

Dipole/dipole contribution:

$$E = 14.4 \sum_i \sum_j \frac{\mu_i \mu_j}{D_\mu r_{ij}} (\cos \alpha_i \cos \alpha_j - 3 \cos \alpha_i \cos \alpha_j)$$

where the value 14.4 converts the result from ergs/mole to kcal/mole, μ_i and μ_j are the angles between the two dipoles, α_i and α_j are the angles which the dipoles form with the vector r_{ij} , connecting the two at their midpoints, and D_μ is the effective dielectric constant.

Dipole/charge contribution:

$$E = 69.1 \sum_i \sum_j \frac{q_i \mu_j}{r_{ij}^2 \sqrt{D_\mu D_q}} (\cos \alpha_j)$$

where the value 69.1 converts the results to units of kcal/mole.

Bond dipole parameters, μ , for each atom pair are stored in bond stretching parameter table of the Chem3D software or may be obtained from the literature or other available databases, such as, for example, Cambridge Structure Database, or experimentally. The charge q is stored in the Molecular Mechanics (MM2) atom types table. The molecular dielectric is set to a constant value between 1.0 and 5.0 in the MM2 Atom types table.

Non-bonded Energy

The second parameter which may be manipulated and balanced is Non-bonded Energy. Molecular mechanics describes the energy of a molecule in terms of a classically derived potential energy functions and the parameters used for their evaluation are known as "force field" parameters. Molecular mechanical methods are based on the following principles:

- Nuclei and electrons are lumped together and treated as unified atom-like particles.

- Atom-like particles are regarded as spheres.

- Bonds between particles are viewed as harmonic oscillators and therefore subject to principles of harmonic conservation of energy.

- Non-bonded interactions between these particles are treated using potential functions derived from classical mechanics.

- Individual potential functions are used to describe the different interactions; including bond stretching, angle bending, torsional or bond-twisting energies and non-bonded or through-space interactions (the interactions of most concern in the subject liquid system).

- Potential energy functions rely on empirically derived parameters, e.g., force constants, equilibrium values, that describe the interactions between sets of atoms.

- The sum of interactions determine the spatial distribution or conformation of atom-like particles.

- Molecular mechanical energies have no meaning as absolute quantities. They can only be used to compare relative steric energies between two or more conformations of the same molecule.

Molecular theory typically treats atoms as spheres and bonds as springs. The mathematics of spring deformation (Hooke's Law) is used to describe the ability of bonds to stretch, bend and twist. Non-bonded atoms defined as greater than two atoms apart, interact through van der Waals attraction, steric repulsion, and electrostatic attraction/repulsion described above. These properties are easiest to describe mathematically when atoms are assumed to be spheres of characteristic equal radii.

The total potential energy, E_{TP} , of a molecule can be described by the following summation:

$$E_{TP} = E_s + E_b + E_t + E_{NBI}$$

where E_s is Stretching Energy, E_b is Bending Energy, E_t is Torsion Energy and E_{NBI} is Non-bonded Interaction Energy. The first three terms are the so-called bonded interactions. In general, these bonding interactions can be viewed as a strain energy imposed by a model moving from some ideal zero-strain conformation. The last terms, which represents non-bonded interactions, is the variable which is of most concern for the present liquid compositions.

The non-bonded energy represents the pairwise sum of the energies of all possible interacting, non-bonded atoms i and j with a pre-determined "cut-off" distance. The non-bonded energy accounts for repulsive forces experienced between atoms at close proximities, defined as less than 2 Å and for the attractive forces felt at longer distances, defined as greater than 2 uniform molecular radii. It also accounts for their rapid fall-off as the interacting atoms move farther apart by a few Angstroms.

Repulsive forces dominate when the distance between interacting atoms becomes less than the sum of their contact radii. This repulsion can be modelled by the following equation which combines an exponential repulsion with an attractive dispersion interaction ($1/R^6$):

$$E_{\text{van der Waals}} = \sum_i \sum_j \epsilon (290,000 e^{-12.5/R} - 2.25 R^{-6})$$

where

$$R = \frac{r_{ij}}{R_i^* + R_j^*}$$

where R_i^* and R_j^* are the van der Waals (VDW) radii of the atoms, epsilon (ϵ) is the depth of attractive potential energy and consequent relative ease with atoms can be pushed together and r_{ij} is the actual distance between the atoms.

At short distance, the above equation favors repulsive over dispersive interactions. To compensate for this at short distance ($R \leq 3.331 \text{ Å}$) this term is replaced with:

$$E_{\text{van der Waals}} = 336.2 \sum_i \sum_j \epsilon R^{-2}$$

For certain interactions, values in the VDW interactions parameter table of the ChemPro 3D software package are used instead of those in the MM2 atom types table. These situations include interactions where one of the atoms is very electronegative relative to the other, such as in the case of water.

Polarisability

The third parameter allowing for modulation towards the balance of medicament and carrier system is polarisation.

Polarisability values are calculated by Chem3D software using the following equations. Of special concern is the orientation polarisation (P_d) caused by the preferential alignment of permanent dipoles in the direction of the electrical, or in this case, the bio-electrical field. To compute P_d , the magnitude of the dipole moment M induced in a molecule by the field acting on it must be factored in. It is assumed that this induced moment is proportional to the strength of the field F , so that:

$$m = \alpha F$$

The proportionality factor α is called "polarisability." It is the induced moment per unit of field strength. Note that α has the dimensions of volume since:

$$\frac{Qr}{(Q/r^2)} = r^3$$

The polarisability of a hydrogen atom is $4.5a^3$, which is close to the volume of a sphere of radius equal to that of the Bohr orbit, $4/3\pi a_0^3 = 4.19a_0^3$. The polarisability of an atom is a good measure of its volume.

If the dielectric is not a gas, as is the case with the present liquid compositions, the influence of the surrounding molecules has to be accounted for in order to estimate the field that acts to polarise a given molecule or atom-like particle. For gases at high temperatures, for non-polar liquids, and for dilute solutions of polar solutes in non-polar solvents, the effective field F is often taken to be:

$$F = E + \frac{4\pi}{3} P$$

It follows then that

$$m = \alpha \quad E + \frac{4\pi}{3} P$$

from which is obtained

$$P_m = \frac{\epsilon - 1M}{\epsilon + 2p} = \frac{4\pi Lc}{3}$$

where $P (= \frac{3}{4\pi} (F-E))$ is the polarisation of individual

molecules, E is electrical energy and P_m is called the molar polarisation.

Polarisation is a calculation in the X, Y, and Z planes and then averaged for each molecular constituent of the carrier and then for the carrier versus the medicament. Bond stretch parameters are not considered. The carrier and medicament are viewed as Atom-like particles. For the same reason energies of vibration and libration defined above, may be ignored.

Hydrophobic Bonding

The fourth and finest refinement of the balance is accomplished by modulating Hydrophobic Bonding. These parameters are calculated from the average potential of each Hydrogen atom on each specific constituent molecule. This last factor becomes particularly important in hydrophobic lipophilic systems and is obviously critical in protein delivery, since ethylated fatty acids replace alcohol or propylene glycol as the primary solvent for the system. This averaged value can be seen as the capacity of the carrier for low polarity, lipid solubility and compares the potential of the Hydrogen molecules on the outer surface of the solvent and solute. Hydrophobic Bonding values may be calculated by Chem3D software.

In practice, a data base on the primary, secondary, and tertiary ingredients of a standard delivery system as well as alternate solvents and modifiers for medicaments requiring a different approach such as proteins or very large polymerized molecules will be established. By "primary," "secondary" and

"tertiary" is meant ingredients which exert major or gross changes in system properties, e.g. dipole moments, van der Waals forces, etc. (primary); ingredients which make only small changes in system properties (secondary) and ingredients which can be used for "fine-tuning" the system properties to match the properties of the solute (tertiary).

The following tables are typical data sheets generated by the Chem3D software. These charts confirm the independent experimental solubility data and also, in Tables 1-3, show how modulation of the carrier system allows a higher dose of the test medicament, Diosgenin (MW=414.61). Table 1 shows balance (and maximum solubility) at 0.25 grams in a typical Stock Delivery System (SDS) according to the invention; Table 2 shows that modulating the system by adding isopropyl alcohol increased the solubilized dose to 1.2 grams, a nearly 5-fold increase. Table 3 shows that when the van der Waals forces of the delivery system with and without drug are mismatched, the system becomes unstable, namely, the solubility limit of the drug is exceeded and a precipitate forms when the composition is allowed to stand overnight.

It is pointed out, however, that the formulations shown in the following Tables, and which are based on the above described Stock Delivery System, were originally prepared without benefit of the use of the Chem 3D software and included omission of several different modifiers. Modifications to the SDS to effect solubilization and increase solute solvent ratios were made by the inventor on the basis of knowledge of how and where the solute (drug) works in the body and using this information to make intuitive predictions of how the solute would interact with the surrounding molecules of the SDS, such as induced polarities relative to other molecules; induction of electric fields due to influence of surrounding molecules; hydrophobic versus hydrophilic properties, etc., while always taking into consideration the desired functional effects contributed by each ingredient. Thus, it should be understood that these tables

5 provide a more rationalized basis and unifying theory of the
operation of the invention and should allow for preparing
stable compositions containing different solutes at high
10 solute/solvent system ratios. For example, using computer
5 modelling of chemical structure can often facilitate
understanding of polarizabilities and possible interactions
between the drug and other potential components of the system.
15 Again, any potential component must be compatible with the
active agent, namely, not form or induce a chemical reaction
or covalent bonding.

For any medicament to be delivered, similar numbers may
be generated whereby the carrier system will be balanced
20 against the medicament.

It will be appreciated that the modifications and
15 calculations in the tables follow the same general principles
as described previously for balancing dipole moments using the
sum of mole-moments. In this case, it is the sum of the mole-
25 van der Waals forces which is calculated and which appears to
provide an effective correlation and predictor of success in
20 formulating stable compositions with high solute/solvent
ratios.

It should also be appreciated that the use of computer
software, for chemical structure modelling, such as the Chem3D
software, while speeding up the ability to fine tune the
35 25 transdermal delivery system, is not essential since solubility
and other data can generally be obtained from the literature
or by direct experimentation, using the general guidelines and
concepts discussed previously.

40 As in the case for balancing of dipole moments, in the
30 present invention, the formulation of the solvent carrier
system, which may be the above described SDS or any other
appropriate non-aqueous or aqueous solvent-carrier system for
45 the particular active agent or active agents and the
particular disease or other condition to be treated, may be
35 balanced for mole-van der Waals forces, when the active agent
or agents are added thereto, as a predictor of solubility of
50 the desired amount(s) of active agent(s) by bringing the sum

5 of the mole-van der Waals forces for the solvent carrier
system with active agent(s) to within $\pm 20\%$, preferably within
10 $\pm 15\%$, especially preferably within $\pm 10\%$, and most especially
5 preferably within $\pm 5\%$, of the sum of the mole-van der Waals
forces of the solvent carrier system without the active
agent(s).

15 When the difference between the sum of the mole-van der
Waals forces of the solvent carrier system plus active agent
is greater than about 20%, especially greater than about 15%,
10 of the sum of mole-van der Waals forces for the solvent
carrier system without active agent the desired amount of
active agent will tend to be insoluble in the solvent carrier
20 system or may precipitate from solution upon standing
overnight. In the case of compositions containing two or more
15 active agents, if the mole-van der Waals forces are not
closely balanced, as described above, one or more of the
25 active agents will tend to be insoluble in the solvent carrier
system or otherwise precipitate out of solution.

TABLE 1
Diosgenin Base Solution

Compound	Mole Wt.	Amt. (grams)	Amt./100 cc	Moles	Moles VW Forces	VW Forces
Diosgenin	414.6		0.25 ¹	0.0006	26.88	0.016
Ethanol	46.07	1068.75	54.38	1.18	2.01	2.375
Water	18	56.25	2.86	0.16	0	0
Propylene Glycol	76.01	828	42.13	0.55	4.10	2.272
limonene	136.24	2	0.10	0.0007	6.22	0.0046
Vitamin E	430.17	1	0.50	0.00012	20.60	0.0024
D-Panthenol	205.25	1.05	0.05	0.00026	10.82	0.0028
Methylsulfonyl- methane (MSM)	94.13	2	0.10	0.0011	-0.34	-0.0004
Lauriciden	181.97	5	0.25	0.0014	14.04	0.020
Oxindole	295	0.06	0.003	1.0E-05	13.66	0.0001
Thiopropionic acid	178.21	1	0.05	0.0003	6.61	0.001
Forskolin	410	0.2	0.01	2.5E-05	25.05	0.0006
Totals		1965.31	100			
					stock solution+diosgenin = 4.694	
					stock solution w/out diosgenin = 4.678	
					difference = 0.016	
					percent difference = 0.34%	

¹Solubility limit determined experimentally

TABLE 2
Diosgenin System One

Compound	Mole Wt.	Mole Amt/100 cc	Moles	VW Forces	VW Forces One
Diosgenin	414.6	1.21	0.003	26.88	0.078
Ethanol	46.07	77.73	1.69	2.01	3.395
Isopropyl Alcohol	60.1	8.18	0.14	1.94	0.264
Water	18	2.30	0.13	0	0
Propylene Glycol	76.01	10.04	0.13	4.10	0.541
limonene	136.24	0	0	0	0
Vitamin E	430.17	0	0	0	0
D-Panthenol	205.25	0	0	0	0
MSM	94.13	0	0	0	0
Lauriciden	181.97	0.3	0.00	14.04	0.023
Oxindole	295	0.06	0.0002	13.66	0.003
Thiopropionic acid	178.21	0	0	6.61	0
Forskolin	410	0.2	0.0005	25.05	0.012
Totals		100	Diosgenin SysOne Mole	4.316	
			STOCK SOL.	4.238	
			Diosgenin SysOne minus Stock Sol.	0.07	
			Percent Difference	1.84	

'Stable solution; effective for transdermal delivery

TABLE 3
Diosgenin System Two

Compound	Mole Wt.	Amt/100 cc	Moles	Mole VW Forces	VW Forces
Diosgenin	414.6	1.5 ¹	0.0036	26.88	0.097
Ethanol	46.07	77.49	1.682	2.01	3.385
Isopropyl Alcohol	60.1	8.16	0.136	1.94	0.264
Water	18	2.29	0.127	0	0
Propylene Glycol	76.01	10.00	0.132	4.10	0.539
limonene	136.24	0	0	0	0
Vitamin E	430.17	0	0	0	0
D-Panthenol	205.25	0	0	0	0
MSM	94.13	0	0	0	0
Lauriciden	181.97	0.3	0.0016	14.05	0.023
Oxindole	295	0.06	0.0002	13.66	0.003
Thiopropionic acid	178.21	0	0	6.61	0
Forskolin	410	0.2	0.0005	25.05	0.012
Totals		100	Diosgenin Sol Mole VWF Two	4.323	
			STOCK SOL.	4.226	
Diosgenin Sys Two minus Stock Sol. 0.097					
Percent Difference					
2.30					

¹Solution not stable; precipitate forms upon standing overnight.

5 The following Table 4 illustrates how the balancing of
molar van der Waals forces can be utilized as a predictor of
the solubilization of amitriptyline in the stock delivery
10 system. In this case the calculations for balancing molar van
5 der Waals forces were made first using the Chem3D software and
the solutions were thereafter formulated in the laboratory.
The amount predicted to dissolve, 2.08 gm per 100 c.c., was
15 within experimental error of the actual amount which would
dissolve in the laboratory experiment. In this case, the
10 system was balanced by increasing the amounts of
methylsulfonylmethane and ethanol and decreasing the amount of
propylene glycol.
20

TABLE 4

	Mole Wt	SDS Ant/100	SDS Moles	Mod.SDS Amt/100	Moles	VW Forces	SDS+Drug VDW-Molar	SDS+Drug VDW-Molar
Amtriptyline	277.41	2.00	0.007	2.08	0.0075	15.99	0.115	0.120
MSM	94.13			0.20	0.0021	-0.39		-0.0008
Ethanol	46.07	54.38	1.18	61.99	1.35	2.01	2.375	2.708
Water	18	2.86	0.16	1.86	0.16	0	0	0
Propylene glycol	76.01	42.13	0.55	33.70	0.44	4.10	2.272	1.817
limonene	136.24	0.10	0.0007	0.10	0.0006	6.22	0.005	0.004
Vitamin E	430.17	0.05	0.0001	0.05	9E-05	20.60	0.002	0.002
D-panthenol	205.25	0.05	0.0003	0.05	0.0002	10.81	0.003	0.002
MSM	94.13	0.10	0.001	0.10	0.0009	-0.39	-0.0004	-0.0003
Lauriciden	181.97	0.25	0.001	0.25	0.001	14.05	0.020	0.016
Oxindole	295	0.003	1E-05	0.003	8E-06	13.66	0.0001	0.0001
Thiopropionic acid	178.21	0.05	0.0003	0.05	0.0002	6.60	0.002	0.002
Forskolin	410	0.01	2.5E-05	0.01	2E-05	25.05	0.0006	0.0005
				100		SDS+Drug =	4.794	4.670
						SDS =	4.679	

5

10

15

20

25

30

35

40

45

50

55

The following Table 5 illustrates the calculation of the mole-moment for a typical Stock Delivery System (SDS) according to the invention:

Table 5

Compound	Mole Wt	SDS Amt Used	Amt/100	Moles	dipole Moment	Mole Moment
Ethanol	46.07	1068.75	54.38	1.18	1.78	2.10
Water	18	56.25	2.86	0.16	1.85	0.29
Propylene Glycol	76.01	828	42.13	0.55	1.45	0.80
limonene	136.24	2	0.10	0.0007	0.365	0.0003
Vitamin E	430.17	1	0.05	0.0001	0.835	9.9E-05
D-panthenol	205.25	1.05	0.05	0.00026	4.33	0.001
MSM	94.13	2	0.10	0.0011	4.51	0.005
Lauriciden	181.97	5	0.25	0.0014	3.08	0.004
Oxindole	295	0.06	0.003	1.03E-05	1.42	1.5E-05
Thiopropionic Acid	178.21	1	0.05	0.00029	3.94	0.001
Forskolin	410	0.2	0.01	2.5E-05	4.48	0.0001
		1965.31	100			
					SUM Mole Moments	3.20

Table 6 shows van der Waals force values for various hormonal active agents:

Table 6

<u>Hormone</u>	<u>VW Forces</u>
Testosterone	16.17
Estrone	13.74
Estradiol	14.87
Estriol	13.89
DHEA	16.48
17 OH Pregnenolone	18.16
Pregnenolone	16.78
Progesterone	15.93
Diosgenin	26.88

Use of the invention methodology for forming a topical composition for transdermal delivery of hydroxyzine at a predetermined or target dosage of about 45 to 50 mg per cubic centimeter is illustrated in the following Table 7:

TABLE 7

Compound	Mole Wt	SDS ¹ Amt/100	H-1 ² Amt/100	H-2 ³ Amt/100	Sol Moles	Two Moles	dipole Moment	Mole Moment	VW Forces
Hydroxyzine	374.91	5.0	5.0	4.55	0.013	0.012	0.57	0.0076	22.72
MSM	94.13		2.0	1.0	0.021		4.51	0.096	-0.39
Ethanol	46.07	54.38	54.38	58.07	1.18	1.26	1.78	2.10	2.01
Water	18	2.86	2.86		0.16		1.85	0.29	0
Propylene Glycol	76.01	42.13	42.13	38.30	0.55	0.50	1.45	0.804	4.10
limonene	136.24	0.10	0.001	0.10	0.0007		0.36	0.0002	6.23
Vit E	430.17	0.05	0.051		0.0001		0.83	0.0001	20.00
D-panthenol	205.25	0.05	0.053		0.003		4.33	0.001	10.82
MSM	94.13	0.10	0.10		0.001		4.51	0.005	-0.39
lauriciden	181.97	0.25	0.25		0.001		3.08	0.004	14.05
Oxindole	295	0.003	0.003		1E-05		1.42	1.5E-05	13.66
Thiopropionic acid	178.21	0.05	0.05		0.0002		3.94	0.001	6.61
Forskolin	410	0.20	0.20		0.005		4.48	0.002	25.05

¹Initial Attempt added Hydroxyzine to Stock Sol.²First modification added additional MSM³Second modification increased Ethanol and reduced additional MSM.

Table 7 (continued)

		H-O Mole-VDW	H-1 Mole-VDW	H-2 Mole-VDW
10	5	0.303	0.303	0.276
			-0.0080	-0.0083
		2.375	2.375	2.536
		0	0	0
		2.272	2.272	2.065
		0.0046	0.0046	0.0042
15	10	0.0024	0.0024	0.0022
		0.0028	0.0028	0.0026
		-0.0004	-0.0004	-0.0004
		0.0196	0.0196	0.017
		0.00014	0.00014	0.0001
	15	.0019	0.0019	0.0017
20		0.0006	0.0006	0.0006
		4.982	4.973	4.898

20 Although not wishing to be bound by any particular theory
 25 of operation, it is believed that the most adequate theory
 describing how the medicament finds its way, once inside the
 body, to the intended target site, is the so-called
 "information theory." This theory asserts that medicaments
 30 25 are biologically active compounds for which the body develops
 particular affinities when challenge is present due to
 degenerative disease, infection or trauma. The affected
 tissues selectively attract and bind these substances as they
 35 encounter them in humor or tissue mediums while normal tissues
 30 seek to deflect the compounds away. Once the carrier
 medicament-complex arrives in the vicinity of the diseased or
 "abnormal" tissue, the attraction of the tissue receptors
 40 overcomes the weak association between the carrier and the
 medicament and the medicament is released intact and taken by
 35 the needy tissue. By a similar mechanism modifying agent
 components may be stripped from the complex prior to arriving
 at the needy tissue.

45 Examples of medicaments which may be incorporated in the
 transdermal delivery system of this invention are not
 40 particularly limited. Generally, any medications previously
 used or suggested as useful for delivery by any means,
 50 including transdermally, whether by patch or ointment or other

5 topical formulation, may be used in this invention. Some
areas where it is envisioned that the subject TDS will have
particular benefits include pain relief (for safer dose of a
10 prescription or non-prescription analgesic locally to the site
5 of pain); antibiotic delivery, e.g., Ciprofloxacin (permitting
higher dosages at the locus of the infection to above safe
systemic levels); corticosteroids (for treating inflammatory
15 indications with delivery bypassing the liver and minimizing
systemic side effects); hormone replacement therapy (e.g., to
10 deliver tri-estrogens to the non-carcinogenic androgen pathway
along with the inclusion of mechanisms to offset the negative
cosmetic side effects of this pathway); isoflavonoid cancer
20 therapies (allowing high concentrations); hypertoxic
chemotherapies (to raise local concentrations with reduced
15 impact systemically).

25 More generally, any of the drugs listed in, for example,
The Merck Index, or other pharmacopeia, may be used. For
example, mention may be made of hormones, such as, DHEA
sulphate, 17-hydroxy pregnenolone, testosterone, tri-estrogen;
20 topical anesthetics, such as, lidocaine, procaine,
30 dimethocaine, salicylic alcoholic; analgesics, such as, for
example, mophine, Demerol®, Fentanyl®, sufentanil,
acetaminophen, acetylsalicylic acid, buccetin, difenamil,
enfamnic acid, etodolac, fenoprofen, Ibuprofen, naproxen,
35 suprofen; steroids, such as, for example, pregnenolone,
pregnenolone acetate, progesterone; ACE-inhibitors;
 α -adrenergic agonists; β -adrenergic agonists;
 α -adrenergic blockers; β -adrenergic blockers; adrenocortical
40 steroids; adrenocorticotrophic hormones; alcohol deterrents;
30 anabolic steroids; androgens, such as testosterone;
anorexics; antacids; anthelmintics; antiacne and keratolytics;
antiallergic, decongestants, antihistamines, glucocorticoids;
45 antialopecia agents; antiandrogens; antianginals;
antiarrhythmics; antiarthritic/antirheumatic; antiasthmatic;
35 antibacterial (antibiotics), e.g., Ciprofloxacin, antifungal
and antiviral agents; antineoplastics; anticholinergics;
50 anticoagulants; anticonvulsants; antidepressants, e.g.,

5 5-hydroxytryptophan; antidiabetics; antidiarrheal agents;
antidiuretics; antidotes (e.g., acetaminophen poisoning,
cyanide poisoning, heavy metal poisoning); antisyskinetics;
10 anti-eczematic agents; antiemetics; antiestrogens;
5 antihistamines; antihyperlipoproteinemics;
antihyperphosphatemics; antihypertensives, such as, e.g.,
clonidine, or other "beta-blockers"; antihyperthyroids;
antihypotensives; antihypothyroids; anti-inflammatory
15 (steroidal and non-steroidal, including, for example, the
10 above-exemplified analgesics and other NSAIDs and steroidal
inflammatories); antimalarial; antimigraines; antineoplastic
agents; antiparkinsonian agents; antipruritics;
20 antipsoriatics; antipsychotics; antipyretics; antiseptics and
disinfectants; antispasmodics; antithrombotics; antitussives;
15 antiulceratives; anxiolytics; astringents; benzodiazepine
agonists; bronchodilators; calcium channel blockers;
25 cardiotonics; chelating agents; choleretics; cholinergics;
central nervous system (CNS) stimulants; digestive aids;
diuretics; enzymes; estrogens; glucocorticoids; gonad-
20 stimulating principles; gonadotropic hormones; other
30 hormonal-type substances, such as, for example, melatonin,
serotonin, liothyronine, histamine H₂-receptor antagonists;
immunomodulators; immunosuppressants; lactation stimulating
hormones; LH-RH agonists; lipotropics; monoamine oxidase
35 25 inhibitors; muscle relaxants; narcotic antagonists; oxytocic
agents; progestogens; prolactin inhibitors;
prostaglandin/prostaglandin analogs; protease inhibitors;
sedatives and hypnotic agents; vasodilators (cerebral,
40 coronary and peripheral); vasoprotectants; vitamins.
30 In particular, the present invention may offer its most
notable benefits in connection with active agents of high
molecular weights for which prior known topical transdermal
45 delivery systems were not effective or applicable. Thus, the
compositions of this invention are highly useful and effective
35 for active agents having molecular weights in excess of about
325 Daltons, especially higher than about 350D, more
50 especially higher than about 375D and most especially higher

5 than about 400D, for example, 500D and higher. Extremely high
molecular weight substances such as calcitonin (MW=4500);
human growth hormone (MW=22,000) and other hormones,
10 polypeptides and protein, may be solubilized in accordance
5 with this invention by appropriate selection of solvents,
e.g., fatty acid, and utilizing appropriate phospholipid
chemistry for the oil phase and hydrophilic/lipophilic
15 modulation by appropriate modifying agents. Moreover, the
compositions of this invention may be formulated to delivery,
10 per unit dosage, usually about 1cc, at least about 0.25 mg,
especially at least about 0.5 mg, especially, up to about 1 mg
or higher of active ingredient, including such high molecular
20 weight substances as described above.

Moreover, the effective dosage of the medicaments are
15 generally substantially less than the effective dosage when
administered orally or intravenously or intramuscularly; and a
25 rule of thumb is that topical transdermal dosages are
approximately one-seventh of the oral dosage. However, higher
or lower dosages may be required or advantageous depending on
20 the symptoms, whether intended for local or systemic
administration, etc.

The invention will now be described with reference to the
following non-limiting illustrative examples.

35 In the following examples the above described SDS was
25 used, in the amounts indicated. Unless otherwise noted all of
the ingredients are USP grade.

Example 1

40 The following composition (lotion) using the above
described Stock Delivery System (SDS) is prepared with
30 Diosgenin ((25R)-Spirost-5-en-3 β -ol) as active ingredient;
diosgenin is a large (MW = 414.6), difficultly soluble soy
isoflavone:
45

54

<u>Compound</u>	<u>Function</u>	<u>Amount (grams)</u>
Diosgenin	Active	4.5
95% Ethanol/Sec-butanol	Primary Solvent	410 c.c.
SDS	Primary Delivery	90 c.c.
5 Alpha lipoic (Thioctic) Acid	Complexer	0.5
Methyl Sulfonyl Methane	Complex Former	0.5
3,3'-Thiodipropionic Acid	Complexer	0.2

A second lotion incorporating other soy isoflavanone compounds is prepared as follows:

<u>Compound</u>	<u>Function</u>	<u>Amount (grams)</u>
Genistein	Active	5.0
Daidzein	Active	5.0
Biochanin A	Active	5.0
Phosphatidyl Serine	Complexer	25 c.c.
15 SDS	Primary Delivery	500 c.c.

In the above formula, daidzein is 4',7-dihydroxyisoflavone. Biochanin is the 4'-methyl ether of genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4',5,7-trihydroxyisoflavone).

These two formulations when used in combination, are expected to be useful in the treatment of prostate cancer.

Example 2

A hormone replacement therapy formulation, especially useful in the treatment of Benign Prostatic Hyperplasia (BPH) using a lower concentration of soy isoflavanones, than in the formulations of Example 1, again in the form of a lotion, is prepared with the following ingredients:

<u>Compound</u>	<u>Function</u>	<u>Amount (grams)</u>
SDS	Primary Delivery	500 c.c.
30 Diosgenin	Active	2.5
Dehydroepiandrosterone	Skin Stabilizer/Active	7.5
Pregnenolone acetate	Skin Stabilizer/Active	1.25
45 Dopamine	Tonic	0.1
Para-aminobenzoic Acid	B Complex Former,	
35 Skin Stabilizer		0.5
2-Diethylaminoethanol	Solute Modifier	0.5
50 Ascorbyl Palmitate	Solvent Modifier	0.15

To enhance the cosmetic tonic properties of the above formulation, various cosmetic additives can be added to the above formula, for example, various plant extracts, such as, for example, extracts of camomile, rosemary, rose hip, horsetail, in amounts of, for example, 10 cc, 5 cc, 5 cc, and 5cc, respectively.

Example 3

A similar, but milder, formulation to that of example 2, more suitable for a female cosmetic product is formulated as follows:

<u>Compound</u>	<u>Function</u>	<u>Amount (grams)</u>
SDS	Primary Delivery System	300
Pregnenolone acetate	Skin Stabilizer/Active	1.0
Diosgenin	Active	0.6
Dehydroepiandrosterone	Skin Stabilizer/Active	0.6
Forskholi (extract, 40%)		65 mg.
3-Hydroxy Tyramine (Dopamine)	Tonic	50 mg.
Camomile Extract	Tonic	5.0 cc
Ascorbyl Palmitate	Solvent Modifier	0.3
Para-aminobenzoic acid	B Complex Factor, Skin Stabilizer	0.5
2-Diethylaminoethanol	Solute Modifier	0.5
Horsetail Extract	Tonic	0.5
3,3'-Thiodipropionic acid	Solute Modifier	0.075
Methyl Sulfonyl Methane	Solvent Modifier	0.5

Example 4

The following female tonic preparation is prepared using the invention Stock Delivery System (SDS) to which pregnenolone acetate (PA) (3 mg/cc) is added:

5

<u>Compound</u>	<u>Function</u>	<u>Amount</u>
SDS + PA	Primary Delivery System	100 cc + 0.3 g
Dehydroepiandrosterone	Skin Stabilizer/Active	1.25 g
Diosgenin	Active	0.1 g
5 Hypericum	Tonic	30.0 cc
Camomile Extract	Tonic	10.0 cc
Rosemary Extract	Tonic	10.0 cc
Rosehip Extract	Tonic	10.0 cc
15 Horsetail Extract	Tonic	10.0 cc
10 Pregnenolone acetate	Tonic	100 mg

Example 5

20

A tonic formulation, suitable for an over-the-counter hormonal product is produced with the following ingredients:

<u>Compound</u>	<u>Function</u>	<u>Amount (grams)</u>
15 SDS with	Primary Delivery System	100 cc
25 Pregnenolone acetate (3 mg/cc)	Active	0.3
Dehydroepiandrosterone	Skin Stabilizer/Active	1.25
Diosgenin	Active	0.1
30 20 Hypericum	Tonic	30 cc
Camomile Extract	Tonic	10 cc
Rosemary Extract	Tonic	10 cc
35 Rosehip Extract	Tonic	10 cc
Horsetail Extract	Tonic	10 cc
25 Pregnenolone acetate	Tonic	100 mg

40

45

50

55

Example 6

Another tonic formulation is prepared with the following ingredients:

<u>Compound</u>	<u>Function</u>	<u>Amount</u>
5 SDS	Primary Delivery System	200 cc
Hypericum	Tonic	20.0 cc
15 Glycyrrhiza	Tonic	20.0 cc
NADH	Tonic	6.0 mg
Dopamine	Tonic	1.0 mg
20 10 Diosgenin	Active	400 mg
Pregnenolone acetate	Tonic	50 mg
Camomile Extract	Tonic	5.0 cc
25 Rosemary Extract	Tonic	1.0 cc
Rosehip Extract	Tonic	1.0 cc

Example 7

The following hormone therapy formulation, designed for female hormone replacement therapy, is prepared:

<u>Compound</u>	<u>Function</u>	<u>Amount</u>
5 SDS +	Primary Delivery	100 cc
15 Ferulic Acid +	Complexer	2.0 g
Estriol	Active	0.6 g
Dehydroepi-		
andosterone	Skin Stabilizer/Active	4.0 g
20 10 Progesterone	Tonic	4.0 g
Pregnenolone		
Acetate	Tonic	0.6 g
25 Testosterone	Tonic	5.0 g
R hormones, e.g.,		
15 Triestrogens	Therapeutic element	per R

In the above formulation 0.5 grams of pregnenolone may be used in place of the 0.6 g of pregnenolone acetate.

Example 8

This example shows the preparation of an aqueous emulsion topical delivery system (OTC) according to the invention for the topical administration of the antibacterial Quaternium 28 (dimethyl benzethonium chloride):

<u>Compound</u>	<u>Function</u>	<u>Amount (wt.%)</u>
Quaternium 28	Active	0.25
Adogen® DHT ¹	Solvent Modifier	4.0
Lauricidin®	Skin desensitizer; anti-inflammatory	6.0
Methylsulfonyl- methane	Solvent Modifier	2.4
Ascorbyl Palmitate	Solute Modifier	0.3
Vitamin E Acetate	Solvent Modifier	0.4
Lemon Oil (Cold pressed, highest food grade)	Solvent Modifier	0.8
D-Panthenol	Solvent Modifier	0.1
Allantoin	Skin Stabilizer	0.3
Emu Oil	Natural Oil	1.0
Cetyl Palmitate	Skin Stabilizer	0.25
Varisoft® 475	Solvent Modifier	4.0
Decanoic Acid Triglyceride	Solvent Modifier	0.3
Water (DI)	Solvent	79.9

The above ingredients are formulated into an emulsion in which the Varisoft, Adogen, Methylsulfonylmethane and Quaternium compounds are present in the aqueous phase; and Lauricidin, Ascorbyl palmitate, Cetyl palmitate, Vitamin E acetate, D-panthenol, allantoin, Emu Oil and decanoic acid triglyceride are present in the organic phase. The lemon oil is present at the interfaces of the oily and aqueous phases.

¹ dihydrogenated tallow dimethyl ammonium chloride; may also function as active ingredient, e.g., as a pain reliver, and also as an anti-irritant.

5 The formulation may be prepared, for example, by
combining the water soluble ingredients and heating to about
60°C. Separately, the organic phase ingredients are combined
10 and heated to about 63°C with care being taken to avoid
5 temperatures above 70°C, preferably, not exceeding about 65°C.
Thereafter, the above water soluble and oil soluble components
are combined by adding the oil phase to the water phase and
15 mixed in a closed, heated vessel. Water is added to achieve a
workable consistency at which time mixing is continued with
10 addition of the remaining water and after cooling to about
50°C the lemon oil is added. Mixing is continued for about 1
20 hour at high, e.g., 1,200 rpm, speed, while continuing to
cool. The vessel should, preferably, remain in the closed
condition during this cooling. The cooling is conveniently
15 accomplished using a cooling jacket on the outside of the
mixing vessel. When the mixture cools to about 35°C it is
25 ready to be transferred to smaller containers for subsequent
handling or transfer.

The mixture becomes quite viscous below about 50°C so
20 appropriate transfer procedures should be adopted.

30 For best results, during the mixing steps, the contents
in the mixing vessel should be maintained at a level such that
the depth of any vortex formed during mixing is about 25% of
the depth in the vessel. As expected, the vortex depth will
35 25 tend to increase as the temperature decreases and thickening
increases. The mixing should be accomplished under conditions
which avoid aeration.

Example 9

40 This example describes the results of an animal (mouse)
30 study performed at St. Bartholomew's and The Royal London
School of Medicine and Dentistry, Department of Experimental
Pathology, to establish the efficacy of the topical delivery
45 system, based on the Stock Delivery System of this invention
for transdermal delivery of Cystamine (2,2'-

dithiobisethanamine). A Murine Chronic Granulomatous Air-Pouch Model was used for evaluation of the delivery of the drug with SDS versus a control vehicle alone; control vehicle plus drug; and SDS alone.

The Air-Pouch Model was selected as an attractive method for studying inflammatory processes since rodent air pouch has been shown to develop into a structure resembling the synovium of diarthrodial joints and in view of ease of induction and possibilities of serial sampling of fluid and tissue. In addition, the air pouch has been developed further in mice for use in the examination of the angiogenic response. The murine chronic granulomatous air pouch is advantageous for study in view of the ease of therapeutic manipulation in this species used and, further, the development of the vasculature may be readily assessed by dye incorporation assays. The metabolic responses of the lining cells of the murine air pouch was assessed for comparison to the enzyme induction seen in rheumatoid synoviocytes, and the model subsequently used for assessing the potential of varying agents to modulate the angiogenic response.

In this study, 1 milligram (mg) of cystamine was added to 0.5 cc of Standard Stock Solution (SDS) as previously described, or to a control vehicle (aqueous isopropanol). In each case, the active ingredient (cystamine) was administered in an amount of 30 mg per kilogram of body weight.

Mice (TO or BALB/c, for hormone studies, 30 ± 5 g) were lightly anaesthetized with halothane. Three milliliters of air were injected subcutaneously into the scruff of the neck using a 25G needle. The shape of the air pouch was controlled by manipulation during inflation. One day later, 0.5 ml Freund's complete adjuvant supplemented with 0.1% croton oil was injected into the air pouch using a 21G needle. Animals were killed at various time points for assessment of pouch vascularity, histology and cleared air pouch preparations.

Vascularity was assessed by a modified form (see Kimura et al, [need citation] 1986) of the Carmine Red Vascular Casting technique. Mice were anaesthetized using hypnorm/hypnovel and kept warm on a heated box at 40°C for 10 minutes. One milliliter (1 ml) of 25% carmine red dye in 10% gelatin at 40°C was injected into the tail vein of each mouse. Cadavers were chilled at 4°C for 4 hours and the granulomas dissected free. Granulomas were weighted after drying in an oven for 2 days at 56°C. The dried granulomas were digested for 24 hours at 56°C in 0.9 ml of digestive solution (12 units ml⁻¹ papain in 0.05M phosphate buffer, pH 7.0, supplemented with 0.33 g/liter N-acetyl cysteine) for cotton-wrapped cartilage granulomas and 9 ml for air pouch granulomas. A volume of 0.1 ml or 1 ml of 4M sodium hydroxide (for each type of granuloma, respectively) was mixed well with each digest. The digests were centrifuged at 2000g for 10 minutes and filtered through a 0.22 µm nitrocellulose disposable filter. The dye content was measured spectrophotometrically at 490 nm against a standard curve of dye from 1-100 µg/ml. Digests were diluted as appropriate to bring them onto the standard curve and blanked against non-injected control granulomas treated in the same way.

Results are expressed, below, as µg carmine red dye per mg dry tissue mass. In some cases, exudate was recovered from the air pouches at termination, 5M sodium hydroxide added to give a final concentration of 0.5M sodium hydroxide and processed as above to determine carmine content.

<u>Delivery System</u>	<u>Dry Weight of Granuloma (mg)</u>
Control vehicle (CV)	0.114 ± 0.113
CV + cystamine	0.115 ± 0.008
SDS	0.1334 ± 0.009
SDS + cystamine	0.082 ± 0.006 *
	*p=0.0291
SDS/[SDS + cystamine]	**p=0.0003

From the above results, namely, a decrease in dry weight of the granuloma, it is apparent that the SDS is highly effective as a delivery vehicle which, in fact, converts the normally sub-effective dose (30 mg/kg) of cystamine to an effective dose.

Example 10

This example is for an aqueous based weight reducing formula in which caffeine and the conjugated isomer of lineolic acid (CLA) are used as the primary active agents.

The formulation was prepared without use of modelling software.

<u>Ingredient</u>	<u>Function</u>	<u>Amount</u> (parts by weight)
<u>Caffeine</u>	Active	0.05
<u>CLA</u>	Active	1.2
Aescin	Solute Modifier	0.1
Pyridoxal-5- Phosphate (P-5-P)	Active/Vitamin	0.001
Liquorice	Active/Hormone	
(20% glycyrrhizic Acid)	Modulator	0.05
Ephedrine	Solute Modifier	
	Active/CNS Stimulant	0.5
Theophylline	Solute Modifier +	
	Active/CNS Stimulant	1.5
Olive Oil	Solvent Modifier	4.0
Carnitine	Solute Modifier	0.1
MSM	Solvent Modifier	2.0
Ascorbic Palmitate	Solvent Modifier	0.15
Lemon Oil	Solvent Modifier	0.8
Alpha-lipoic acid	Solute Modifier	0.2
Lauricidin	Skin Stabilizer	1.0
Adogen DHT	Solvent Modifier	4.65
Allantoin	Skin Stabilizer	0.3
Vitamin E acetate	Skin Stabilizer	0.25
Dexpantenol	Solvent Modifier	2.0
Water	Primary Solvent	

The above formulation is designed for patients with severe chronic obesity with cardiac complications. Therefore, forskolin is not included in the formula in view of its cardiostimulant effects which, although only short-lived, is considered to present an unnecessary risk. However, under appropriate circumstances forskolin or equivalent may be added to the formulation with expected improvement in speed of absorption and total uptake. In addition, by more closely balancing moles-van der Waals forces to within about 15% or less further improvements in the penetration and performance characteristics would be achieved.

Example 11

This example is for a pain treating composition, formulated as an ointment.

<u>Ingredient</u>	<u>Amount (parts by weight)</u>
Merguard	0.125
Verisoft 475	3.6
Adogen DHT	3.2
Lauricidin	6.0
MSM	2.4
Ascorbic Palmitate	0.3
Vitamin E Acetate	0.4
Lemon Oil	0.8
Dexpantenol	0.1
Allantoin	0.7
Olive Oil	1.0
Cetyl Palmitate	0.25
Dimethyl Benzethonium	
Chloride	0.25
Decanoic Acid	
Triglyceride	0.7
Sorbitan Palmitate	0.7
Water	5.225

The sum of the total system moles-van der Waals forces is 0.598 while for the total system less active agent (Verisoft 475) the sum of moles-van der Waals forces is 0.516.

Example 12

The following composition is an aqueous cream formulation designed for promoting cellulite removal.

<u>Ingredient</u>	<u>Amount (parts by weight)</u>
5 CLA	0.3
Aescin	0.1
P-5-P	0.001
15 Liquorice (20%)	0.05
Ephedrine	0.5
10 Theophylline	1.5
Olive Oil	2.0
Carnitine	0.3
20 MSM	2.0
Ascorbic Palmitate	0.015
15 Lemon Oil	0.8
Alpha lipoic acid	0.2
25 Lauricidin	2.0
Adogen DHT	4.65
Allantoin	0.3
20 Vitamin E acetate	0.25
30 Dexpanthenol	2.0
Propylene Glycol	2.0
Water	

The difference between the moles-van der Waals forces of the carrier/solvent system (0.506) and the total system (carrier/solvent plus active ingredient - theophylline) (0.552) is about 8.33%

Example 13

This example describes the results of an in vitro trial based on the stock delivery system of this invention, for transdermal delivery of morphine (as morphine sulfate), in a Franz Diffusion Cell model.

Evaluation of Morphine Formulation

This morphine formulation is designed as a therapeutical product for cancer pain relief.

Presently, transdermal formulations developed for the purpose of cancer pain relief have not yet been found to be successful for practical use. One reason, is that the level of morphine required to show an analgesic effect is very high, in the order of 70 mg/day (in the case of applying to a 100 cm² area, a transdermal absorption rate of 27 µg/hr/cm² is necessary). If an absorption enhancer strong enough to have such a high level of morphine absorbed transdermally is used, it is inevitable that serious skin irritation will result.

The evaluation of the subject formulation was performed in vitro with skin taken from a hairless rat. Since the barrier ability of the stratum corneum does not differ between in vitro and in vivo status, transdermal absorption may be correlated evaluated with the in vitro skin permeation test.

Experiment

2 kinds of SDS vehicles were used:

SDS-L for topical use - lotion (see Table 8);

SDS-S for systemic use - lotion (see Table 9).

The morphine sulfate was supplied by Sankyo Pharmaceuticals, Japan.

Table 8

<u>Compound</u>	<u>Mole Wt</u>	<u>Amt (g) / 100ml</u>
Morphine Sulfate	668.77	0.25
<u>SDS-L</u>		
MSM	94.13	2
Ethanol	46.07	56.881
water	18	2.862
Propylene Glycol	76.01	42.131
limonene	136.24	0.102
Vit E	430.17	0.051
Dexpanthenol	205.25	0.053
MSM	94.13	0.102
Lauriciden	181.97	0.254
Oxindole	295	0.003
Thiopropionic Acid	178.21	0.051
Forskolin	410	0.010

Table 9

<u>Compound</u>	<u>Mole Wt</u>	<u>Amt (g) / 100ml</u>
Morphine Sulphate	668.77	0.25
<u>SDS-S</u>		
Ethanol	46.07	57.243
Acetone	58.08	5.0
Propylene Glycol	76.01	42.131
limonene	136.24	0.102
Vit E	430.17	0.051
Dexpanthenol	205.25	0.053
MSM	94.13	0.102
Lauriciden	181.97	0.254
Oxindole	295	0.003
Thiopropionic acid	178.21	0.051
Forskolin	410	0.010
<u>Balancing Compoents</u>		
ATP	507.17	0.25
Limonene	136.24	1.0
DMAE	89.14	1.0
Benzyl Alcohol	108.44	0.5
MSM	94.13	3.0

The standard stock solution, SDS-L, is not optimized for system perfusion. However, for the systemic stock solution, SDS-S, the additional MSM, additional limonene, DMAE and benzyl alcohol are added to the solution to balance the formula as previously described. Thus, the sum of the products van der Waals-moles for the ingredients of SDS-S (namely, ethanol, acetone, propylene glycol, Vitamin E, dexpanthenol, methylsulfonylmethane (MSM), lauriciden, oxindole, thiopropionic acid, and Forskolin) is 4.742, whereas the sum of the products VDW-moles for the final formula (including morphine sulfate, additional MSM, additional limonene, dimethylaminoethanol (DMAE), and benzyl alcohol) is 4.861, a difference of only about 2.44%.

5 additional limonene, dimethylaminoethanol (DMAE),
and benzyl alcohol) is 4.861, a difference of only about
2.44%.

10 Skin Permeation Test

5 A vertical standing static type Franz Cell is employed.
The receptor phase is maintained at 37°C by circulating
15 uniformly heated water.

Skin is taken from the abdomen of a hairless rat, male,
12 weeks of age, purchased from Charles River Laboratories,
10 and the skin is stored for two weeks at -60°. Just before use
the skin is gently thawed to room temperature and then cut
20 into circular shapes with a diameter of 3.5 cm and set into
the Franz Cell device.

The topical and systemic preparations are prepared by
15 adding 28 mg of morphine sulfate to 10 ml each of SDS-L and
SDS-S while stirring at room temperature until the morphine
sulfate is completely dissolved and allowing the mixture to
stand overnight, while tightly sealed.

30 In order to compare effectiveness of the formulations as
20 a lotion and as a patch, the evaluations are made on two kinds
of applications: open condition, which mimics the application
of a lotion formulation and, closed condition, which mimics
the application of a patch formulation, as follows:

35 (i) Open Condition

25 At the beginning of the skin permeation test, 1 ml of the
morphine sulfate combined with SDS-L or morphine sulfate
combined with SDS-S is placed in the Donor chamber of the
40 Franz Cell. Air is introduced for 10 minutes by a drier to
volatilize the volatile components in the vehicle. The Donor
30 chamber is kept open until the completion of the test.

45 (ii) Closed Condition

At the beginning of the skin permeation test, 1 ml each
of the morphine sulfate combined with SDS-L or morphine
sulfate combined with SDS-S is placed in the Donor chamber of
35 the Franz Cell. The Donor chamber is kept completely sealed
50 until the completion of the test.

Isotonic phosphate buffer, pH 7.2, consisting of 0.033 mM sodium phosphate, 7.4% NaCl and 1% NaN₃ (preservative) is used as the receptor solution.

At each sampling time, established beforehand, 1.8 ml of the solution in the receptor chamber is sampled, and the same volume of receptor solution is added to the receptor chamber.

The concentration of morphine sulfate in each receptor solution sampled is determined quantitatively by HPLC.

Based on the morphine sulfate concentration in the receptor solution obtained as above, the amount of morphine sulfate permeated per 1 cm² of skin is cumulatively calculated, then plotted against each sampling time. On the resulting skin permeation profiles, the region where there is a linear relation between the permeated morphine sulfate concentrations and the sampling times is chosen. Then the linear equation that best fit the region is determined by the least squares method. The "permeation flux" is obtained from the slope and the "lag time" from the time-axis intercept. The tests are repeated three times and the average and standard deviation (SD) of the "permeation flux" and the "lag time" are calculated.

Results

1. pH Values of Morphine Sulfate Combined with SDS-L and Morphine Sulfate Combined with SDS-S

The pH values of vehicle combined with morphine sulfate (at 2.6 mg morphine sulfate/ml) was 6.14 for SDS-L and 5.77 for SDS-S, respectively. Both formulations are non-toxic to the skin.

2. Volatility of Solvent under Open Conditions

Approximately half the volume of the solvent remained (not volatized) after ventilation for 10 minutes with the drier. After extending the test for 29 hours, about 1/10 volume of the solvent still remained in the donor cell.

3. Skin permeation of the Morphine Sulfate from the Stock Solution

Tables 10 and 13 and Figures 1-4 show the cumulative permeated amount of morphine sulfate per 1 cm² of hairless rat skin over time. Table 14 shows the permeation of flux and lag time of morphine sulfate obtained from the permeation profiles in Figure 1. For both SDS-L and SDS-S morphine sulfate is detected in the receptor solution after 6 hours. Thereafter, the permeation flux is approximately twice as fast in SDS-S than in SDS-L. In the case of SDS-L, there is little or no difference in the permeation flux or the lag time between the open conditions and the closed conditions. In the case of SDS-S, there is also little or no difference in the flux or lag time between open and closed conditions.

Table 10 - Amount of morphine sulfate through 1 cm² of hairless rat skin from SDS-L (open condition)

Time (hr)	Amount of morphine sulfate through 1 cm ² of hairless rat skin (ug/cm ²)				
	s-1	s-2	s-3	mean	sd ¹⁾
0	0	0	0	0	0
3	0	0	0	0	0
6	0	0	0	0	0
22	118	6	8	44	64
26	373	44	48	155	189
29	564	141	119	275	251

1) standard deviation

Table 11 - Amount of morphine sulfate through 1 cm² of hairless rat skin from SDS-L (closed condition)

Time (hr)	Amount of morphine sulfate through 1 cm ² of hairless rat skin (ug/cm ²)				
	s-1	s-2	s-3	mean	sd ¹⁾
0	0	0	0	0	0
3	0	0	0	0	0
6	0	0	0	0	0
22	6	22	7	12	9
26	40	179	158	126	75
29	158	327	324	270	97

1) standard deviation

Table 12 - Amount of morphine sulfate through 1 cm² of hairless rat skin from SDS-S (open condition)

Time (hr)	Amount of morphine sulfate through 1 cm ² of hairless rat skin (ug/cm ²)				
	s-1	s-2	s-3	mean	sd ¹⁾
0	0	0	0	0	0
3	0	0	0	0	0
6	0	0	0	0	0
22	67	865	125	352	445
26	290	1140	447	626	452
29	464	1263	694	807	412

1) standard deviation

Table 13 - Amount of morphine sulfate through 1 cm² of hairless rat skin from SDS-S (closed condition)

Time (hr)	Amount of morphine sulfate through 1 cm ² of hairless rat skin (ug/cm ²)				
	s-1	s-2	s-3	mean	sd ¹⁾
0	0	0	0	0	0
3	0	0	0	0	0
6	0	0	0	0	0
22	717	599	1091	802	257
26	1040	940	1256	1079	162
29	1256	1112	1375	1248	132

1) standard deviation

Table 14 - Permeation flux and lag time of morphine sulphate from SDS-L or SDS-S through hairless rat skin

formulation	application method	flux (μg/hr/cm ²)	lag time (hr)
MS-1	open	33±	21±1
	closed	36±	22±0
MS-2	open	65±	16±8
	closed	64±	7±10

Example 14

This example describes the result of an animal (hairless rat) study performed to further establish the efficacy of the topical delivery system, based on the stock delivery system of this invention for transdermal delivery of morphine (mol. Wt. 285.34) and also for acyclovir (mol. Wt. 225.21) and testosterone (mol. Wt. 288.43). The acyclovir and testosterone formulations are shown in Tables 15 and 16, respectively. The morphine formulation is shown in Table 9 above. A pilot trial is performed on three hairless rats, during which a baseline blood sample is drawn, then 1 ml of

the topical delivery system containing a titrated dose of each of the three test drugs is administered to each of the rats. Samples are harvested at 30 and 60 minutes. The results are as follows:

Medicament	Dose in 1 ml	Baseline	30 minutes	60 minutes
Morphine	2.5 mg	0	Ins. Sample	45nmol/L
Testosterone	5 mg	165	1,552ng/dl	1600ng/dl
Acyclovir		0		

In view of these encouraging results a full-scale protocol trial is performed on 15 hairless rats, divided into three groups of five rats each. One group is dosed with the morphine formulation of Table 10, one with the testosterone formulation of Table 11 and one with the acyclovir formulation of Table 12. Samples for the morphine and acyclovir groups are taken at 30 minutes, 60 minutes and 120 minutes. Samples from the testosterone group are taken at Baseline - 0 minutes, 30 minutes and 60 minutes. The results are as follows:

Medicament	Dose in 1 ml	Baseline	30 minutes	60 minutes
Morphine	2.5 mg	0	nmol/L	nmol/L
Acyclovir		0	ng/dl	ng/dl

Medicament	Dose in 1 ml	Baseline	30 minutes	60 minutes
Testosterone	5 mg	165	ng/dl	ng/dl

Testosterone levels are increased 10-fold in one hour. A 2.5 mg dose of morphine, a dose which would be considered insufficient to accomplish a therapeutic outcome if dosed intravenously, provides blood levels equivalent to a 10 mg IV dose. Further, morphine is considered extremely difficult to deliver transdermally due to its highly lipophilic character.

The kinetic outcomes for all three molecules would be sufficient to accomplish therapeutic doses in human beings.

74

Table 15 - Acyclovir Formulation

<u>Compound</u>	<u>Mole Wt.</u>	<u>Amt/100ml</u>
Acyclovir	225.09	
MSM	94.13	3
5 <u>SDS</u>		
Vite	430.17	0.051
Dexpantenol	205.25	0.053
MSM	94.13	0.10
Lauriciden	181.97	0.25
10 Oxindole	295	0.003
Forskolin	410	0.010

The sum of moles-van der Waals forces for the SDS components is 0.0252 while the sum of moles-van der Waals forces for the SDS plus acyclovir and additional MSM is 0.0353.

Table 16 - Testosterone Formulation

<u>Compound</u>	<u>Mole Wt.</u>	<u>Amt/100ml</u>
Testosterone	288.4	5.0
Ethanol	46.07	54.381
20 Water	18	2.862
Propylene Glycol	76.01	42.131
limonene	136.24	0.102
35 Vite	430.17	0.051
Dexpantenol	205.25	0.053
25 MSM	94.13	0.102
Lauriciden	181.97	0.254
Oxindole alkaloid	295	0.003
Forskolin	410	0.010

In order to determine the transdermal absorption of testosterone from this formulation, the formulation is applied to rat skin (n=6) and the amount absorbed through the skin is measured at 0, 30 and 60 minutes. The results obtained are shown in the following Table 17.

Table 17 - Testosterone absorption through the skin

Plasma testosterone, ng/g1

<u>Time</u>	<u>Rat 1</u>	<u>Rat 2</u>	<u>Rat 3</u>	<u>Rat 4</u>	<u>Rat 5</u>	<u>Rat 6</u>	<u>Mean</u>	<u>Median</u>
0	171	50	211	229	366	165	199	191
30	815	152	668	893	1577	1552	943	854
60	542	222	553	1321	2137	>1600	1062	937

Example 15

The following lotion for transdermal delivery of male hormones is prepared.

<u>Compound</u>	<u>Mole Wt.</u>	<u>Amt/100ml</u>
DHEA	288.4	1231
Diosgenin	414.6	0.115
Androstenedione	286.4	3.007
Ethanol	46.07	70.0
Acetone	58.08	
water	18	2.95
Propylene Glycol	76.01	22.0
limonene	136.24	0.10
VitE	430.17	0.06
Dexpantenol	205.25	0.06
MSM	94.13	2.0
Lauriciden	181.97	0.20
Oxindole	295	0.01
Thiopropionic acid	178.21	
Forskolin	410	0.04
Indole 3-Carbinol		
Rosemary		

Example 16

This example is directed to a formulation for transdermal delivery of human growth hormone (HGH) (MW=20,000) using a modified form of the standard stock delivery system according to this invention:

	<u>Amt/100 ml</u>
HGH	0.20
Cyclodextrin	5.0
MSM	1.5
Vitamin E	0.1
Dexpantenol	0.055
Phytantriol	0.025
Oxindole	0.15
Forskolin	0.50

76

	Tween 80	0.924
	Ceterath 20	1.5
	Guaifenesin	0.6
	Inositol	0.6
5	Propylene Glycol	100.0
10	Water	10.0

Example 17

This example illustrates modification of the proportions of the active ingredients and delivery system to match the physiochemical properties (here, van der Waals forces) of the active ingredients and carrier system, to maximize effectiveness of the transdermal delivery of the active ingredients. In this case, the active ingredients, including the combination of Lorazepam and Ibuprofen, provide an anxiolytic or muscle relaxant treatment.

<u>Ingredient</u>	Formula 17-A	Formula 17-B
	<u>Amt/100 ml</u>	<u>Amt/100 ml</u>
Flubiprofen	1.0	0.75
Diazepam	0.5	0.5
20 Ibuprofen	0.8	0.8
Lorazepam	0.3	0.3
MSM	4.0	4.0
30 Ethanol	56.9	56.9
Water	18.0	18.0
25 Propylene Glycol	42.1	42.1
Limonene	0.10	0.10
Vitamin E	0.05	0.05
Dexpantenol	0.05	0.05
35 MSM	0.10	0.10
30 Lauriciden	0.25	0.25
Oxindole	0.003	0.003
Thiopropionic Acid	0.05	0.05
Forskolin	0.01	0.01
Vinpocetine	0.10	0.10
35 Resveratrol	0.02	0.02
40 Emodin	0.01	0.01
Cyclobenzaprine HCl	0.50	0.80
Inositol	0.60	0.60
Guaifenesin	0.60	0.60
40 Prozac	1.0	0.5
GABA	1.0	1.0

For formula 17-A the sum of moles-van der Waals (VDW) for delivery system is 2.892 while for the delivery system and actives, the sum is 5.021. However, for formula 17-B the sum of moles-VDW is 2.838 for delivery system and 2.9687 for delivery system plus actives.

REFERENCES

1. T. K. Ghosh, et al., *Methods of Enhancement of Transdermal Drug Delivery, Parts I, IIa & IIb, Chemical Permeation Enhancers*, Pharm. Tech. 17(3):72-98m 17(4):62-89m 17(5):66-76 (1993).
2. Crouch, James E., *Functional Human Anatomy*, Lea & Fibiger, LOCCN 65-12968, Chapter 6, pp. 88-97, 1965.
3. K. Tojo, *Random Brick Model for Drug Transport Across Stratum Corneum*, J. Pharm. Sci., 76:889-891.
4. S. D. Roy, *Preformulation Aspects of Transdermal Delivery Systems*, In: *Transdermal and Topical Drug Delivery Systems*, Eds. T. K. Ghosh, W. R. Pfister, S. I. Yum, Interpharm Press, Inc., Buffalo Grove, IL, 1997.
5. K. Gjesdal, et al., *Transdermal Nitrate Therapy: Bioavailability During Exercise Increase Transiently after the Daily Change of the Patch*, Brit. J. Clin. Pharmacol. 31:560-562 (1991).
6. K. Tojo, *The Prediction of Transdermal Permeation: Mathematical Models*, In: *Transdermal and Topical Drug Delivery Systems*, Eds., T. K. Ghosh, et al., Interpharm Press, Buffalo Grove, IL, 1997.
7. I. Diez, et al., *A Comparative In Vitro Study of Transdermal Absorption of a Series of Calcium Antagonist*, J. Pharm. Sci. 80:931-934 (1991).
8. W. R. Pfister, et al., *Permeation Enhancer Compatible with Transdermal Drug Delivery Systems, Parts I & II: Selection and Formulation Considerations*, Pharm. Tech. 14(9):132-140, 14(10):56-60.
9. C. D. Vaughn, *Using Solubility Parameters in Cosmetic Formulations*, J. Soc. Cosmet. Chem. 36:319-333 (1985).
10. J. W. Streilein, In: *Immune Mechanisms in Cutaneous Diseases*, Ed. D. A. Norris, Marcel Dekker, Inc., New York, pp. 73-96 (1989).
11. J. Ademola, et al., *Safety Assessment of Transdermal and Topical Dermatological Products* In: *Transdermal and Topical Drug Delivery Systems*, Eds. T. K. Ghosh, et al., Interpharm Press, Inc., Buffalo Grove, IL, (1997).
12. P. Liu, et al., *Quantitative Evaluation of Ethanol Effects on Diffusion and Metabolism of β -Estradiol in Hairless Mouse Skin*, Pharm. Res. 8:865-872 (1991).

5 13. Lubert Stryer, *Biochemistry*, 2nd Edition, Chapter
35, pp. 839-858, W. H. Freeman, Co., New York, (1981).

10 14. Kenneth B. Seamon, et al., *Forskolin: Unique
Diterpene Activator of Adenylate Cyclase in Membranes and
Intact Cells*; PNAS, vol. 78, no. 6, pp. 3363-3367 (June 1981).

15 15. Hermann P.T. Ammon, et al., *Forskolin: From
Ayurvedic Remedy to a Modern Agent*; *Planta Medica*, pp. 473-476
(1985).

15

20

25

30

35

40

45

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

What is claimed is:

- 1 Claim 1. A topical formulation effective for rapid
2 transdermal delivery of an active agent comprising
3 (1) active agent,
4 (2) solvent carrier in which the active agent is soluble,
5 and
6 (3) a substance capable of in vivo stimulation of
7 adenosine 3',5'-cyclic monophosphate (cAMP) or cyclic
8 guanosine-3',5'-monophosphate (cGMP).
- 1 Claim 2. The topical formulation of claim 1 wherein the
2 substance (3) comprises an extract of *Coleus Forskholi*.
- 1 Claim 3. The topical formulation of claim 2 wherein the
2 extract is Forskolin, Colforsin or coleonol.
- 1 Claim 4. The topical formulation of claim 1 wherein the
2 substance comprises Forskolin.
- 1 Claim 5. The topical formulation of claim 1 wherein the
2 substance (3) comprises a member selected from the group
3 consisting of methylxanthines, sarkogenin, sarkosaponin,
4 *Angelica dahuricae* radix, angelic acid, phellopterin and
5 oxypeucedanin.
- 1 Claim 6. The topical formulation of claim 1 wherein the
2 substance (3) comprises at least one of adenosine
3 triphosphate, nicotinamide adenine dinucleotide (reduced) or
4 flavin adenine nucleotide (reduced).
- 1 Claim 7. The topical formulation of claim 1 further
2 comprising methylsulfonylmethane.
- 1 Claim 8. The topical formulation of claim 1 further
2 comprising at least one terpene compound selected from the
3 group consisting of cineol-terpinen-4-ol, genistein, genistin,
4 polyphenol flavinoids, boswellic acid, phytic acid, hypericum,
5 triterpenoids, proanthocyanidins, beta-sitosterol,
6 stigmasterol, campesterol, scutellarein, scutellarin, escin,
7 esculin and *Uncaria Tomentosa*.
- 1 Claim 9. The topical formulation of claim 1 further
2 comprising *Uncaria Tomentosa*.
- 1 Claim 10. The topical formulation of claim 1 further
2 comprising at least one penetration enhancer.

5

1 Claim 11. The topical formulation of claim 10 wherein
2 the penetration enhancer comprises at least one compound
3 selected from the group consisting of 3,3'-thiodipropionic
4 acid, ferulic acid, trans-ferulic acid, α -linolenic acid,
5 ecosapentaenoic acid, cis-9 linolenic acid, docosahexaenoic
6 acid, allantoin, ascorbyl palmitate, conjugated linoleic acid,
7 C₆-C₁₂ mono-, di-, or tri-glycerides, and α -lipoic acid.

10

15

1 Claim 12. The topical formulation of claim 1 further
2 comprising glycerylmonolaurate.

1 Claim 13. The topical formulation of claim 1 further
2 comprising at least one of quaternium 18 or quaternium 27.

20

1 Claim 14. The topical formulation of claim 1 further
2 comprising at least one of N,N-diethylethanolamine or N,N-
3 dimethylethanolamine.

25

1 Claim 15. The topical formulation of claim 1 further
2 comprising at least one steroidal compound selected from the
3 group consisting of dehydroepiandro-sterone, pregnenolone,
4 pregnenolone acetate, and progesterone.

30

1 Claim 16. The topical formulation of claim 1 wherein the
2 active agent is a bioactive substance having a molecular
3 weight of at least about 375D.

35

1 Claim 17. The topical formulation of claim 1 further
2 comprising at least one oily substance selected from the group
3 consisting of fish oils, eicosapentanoic acid, docosahexanoic
4 acid, gamma-linolenic acid, conjugated linoleic acid, medium
5 chain mono-, di-, or triglycerides, and emu oil.

40

1 Claim 18. The topical formulation of claim 1 wherein the
2 solvent system comprises at least one solvent selected from
3 the group consisting of C₂-C₆ monoalcohols and C₂-C₆ polyols.

45

1 Claim 19. The topical formulation of claim 1 which
2 further comprises at least one vitamin selected from the group
3 consisting of Vitamin A, Vitamin C, Vitamin D₃, Vitamin E and
4 Vitamin K1.

50

55

1 Claim 20. A liquid composition effective for transdermal
2 delivery of high molecular weight active agent comprising

3 (1) active agent having a molecular weight of at least
4 about 350D,

5 (2) a solvent system in which the active agent is at
6 least substantially soluble,

7 (3) at least one solvent modifying compound effective for
8 modifying the solvent system to facilitate transdermal
9 delivery of the active ingredient,

10 (4) at least one active agent modifying compound forming
11 a non-covalently bonded complex with the active agent,

12 whereby the active agent is present as a true solution in
13 the solvent system and wherein when applied to living membrane
14 the composition is capable of transdermal delivery of the
15 active agent at a rate of at least about 0.5 mg per cm² per 24
16 hours.

17 Claim 21. A unit dosage form of the liquid composition
18 of claim 20 having a volume of about one cubic centimeter and
19 containing at least about 0.5 milligrams of active agent.

20 Claim 22. The unit dosage form according to claim 21
21 containing about 1 mg of active agent.

22 Claim 23. A liquid carrier composition effective for
23 forming a solution of a given amount of active agent having a
24 given polarity and dipole moment, and which is effective for
25 the transdermal delivery of substantially the entire given
26 amount of active agent having a given polarity and dipole
27 moment, said composition comprising

28 (A) a solvent system in which the active agent is at
29 least substantially soluble; which has substantially the same
30 dipole moment as that of the active agent;

31 (B) at least one solvent modifier having the same
32 morphology as that of the active agent and being an
33 ethylenically unsaturated polar molecule containing a
34 functional group containing a heteroatom selected from the
35 group consisting of at least one of oxygen, nitrogen and
36 sulfur;

5
16 (C) at least one metabolizable solute modifier capable
17 of forming a non-chemically bonded complex with the active
18 agent; and

10 19 (D) at least one source of cellular activation energy;
20 and wherein the sum of the mole-moments of each of the
21 compounds in (A), (B), (C) and (D) is approximately the same
22 as the sum of the mole-moments of each of the compounds in
15 23 (A), (B), (C) and (D) and of said given amount of active
24 agent.

1 Claim 24. The composition of claim 23 further wherein
2 the sum of the mole-van der Waals forces of the compounds in
3 (A), (B), (C) and (D) is approximately the same as the sum of
20 4 the mole-van der Waals forces for the compounds in (A), (B),
5 (C) and (D) and said given amount of active agent.

1 Claim 25. The composition of claim 23 further comprising

25 2 (E) a skin stabilizer for stimulating the body's repair
3 mechanisms in response to transdermal migration of the active
4 agent through the skin.

1 Claim 26. A liquid carrier composition effective for the
2 transdermal delivery of a medicament having a given polarity,
30 3 said formulation comprising

4 (a) at least one non-aqueous non-toxic solvent selected
5 from the group consisting of lower aliphatic mono- and poly-
6 hydroxy compounds;

35 7 (b) limonene, lemon oil or mixture thereof;

8 (c) methylsulfonylmethane;

9 (d) as skin stabilizer, at least one compound selected
10 from the group consisting of aliphatic carboxylic acid having
40 11 from 8 to 32 carbon atoms, an ester of said aliphatic
12 carboxylic acid with an aliphatic alcohol having from 1 to 20
13 carbon atoms, wherein said ester has a total of from 9 to 36
14 carbon atoms, Vitamin D₃, and mixtures thereof;

45 15 (e) as solute modifier, a compound selected from the
16 group consisting of 3,3'-thiodipropionic acid, ester thereof,
17 salt thereof, oxindole alkaloid, polyphenolic flavonoid, sugar
18 adduct of a gluconuride, isoflavones, phosphatidyl serine,
50 19 phosphatidyl choline, vitamin D₃ and Vitamin K₁, and

5
20 (f) ATP or a compound which induces generation of cAMP
21 in situ or cGMP in situ.

1 Claim 27. The composition of claim 26 wherein component
10 2 (f) comprises forskolin.

1 Claim 28. The composition of claim 27 further comprising
2 glycerol monolaurate.

1 Claim 29. The composition of claim 28 further comprising
15 2 dehydroepiandrosterone.

1 Claim 30. A liquid carrier system useful for transdermal
2 delivery of a polar or non-polar medicament which comprises

3 (i) a first solvent comprising at least one solvent
20 4 selected from the group consisting of C₁ to C₆ monoalcohol,
5 propylene glycol, C₁ to C₆ polyol and mixtures thereof;

6 (ii) a second solvent comprising at least one solvent
7 modifier selected from the group consisting of lemon oil, d-
25 8 limonene, and D-panthenol; and

9 (iii) methylsulfonyl methane.

1 Claim 31. A method for forming a composition containing
2 a predetermined amount of active agent of known or determined
30 3 polarity for the topical application to the skin or mucous
4 membrane of a plant or animal for the transdermal delivery of
5 said predetermined amount of active agent contained in said
6 composition, said method comprising

7 selecting at least one solvent in which the active agent
35 8 is at least partially or substantially soluble;

9 selecting modifying agent for each of the at least one
10 solvent and active agent, such that when active agent is
11 dissolved in a solvent system comprising said at least one
40 12 solvent and said modifying agent, there will form a complex of
13 at least one modifying agent weakly associated with the active
14 agent through van der Waals forces and/or hydrogen bond
15 affinities; said modifying agent comprising at least one
45 16 ethylenically unsaturated compound having a polar group and an
17 oxygen, nitrogen or sulfur containing functional group, and at
18 least one compound for balancing at least one molecular
19 property characteristic of the solvent system and active
50 20 agent, said molecular property characteristic being at least

21 one of electrostatic energy, non-bonded energy,
22 polarisability, or hydrophobic bonding, and wherein the
23 amounts of each of the at least one solvent and modifying
24 agent are selected such that the sum of the mole-moments of
25 each of the ingredients of said solvent system closely matches
26 the sum of the mole-moments of each of said ingredients plus
27 active agent, and

28 forming said pharmaceutical composition by mixing each of
29 the active agent and solvent system.

1 Claim 32. The method of claim 31 which further comprises
2 selecting the ingredients of the solvent system and the
3 amounts thereof such that the sum of the mole-van der Waal
4 forces of each of the ingredients of the solvent system
5 closely matches the sum of the mole-van der Waal forces of
6 each of the ingredients plus active agent.

1 Claim 33. The method of claim 31 which further comprises
2 adding to the composition a metabolizable solute modifier
3 which forms a non-covalently bonded complex with the active
4 agent wherein the complex will disassociate during
5 transmigration through the skin or membrane without modifying
6 the structure of the active agent.

1/4




Fig. 1

2/4




Fig. 2

3/4




Fig. 3

4/4




Fig. 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15297

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 7/06, 35/78, 7/48, 7/00
US CL : 424/401, 74, 61, 195.1; 514/846, 847, 860, 944
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/401, 74, 61, 195.1; 514/846, 847, 860, 944

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,529,769 A (CHO et al) 25 June 1996, entire document, especially claims 9.	1-8, 10-11, 16-19
X	US 5,523,090 A (ZNAIDEN et al) 04 June 1996, entire document.	1-8, 10-14, 16-20
X	Database EMBASE on STN, AN 91290543. DASARATHY et al. 'Involvement of second messenger systems' in stimulation of angiotensin converting enzyme of bovine endothelial'. Journal of Cellular Physiology, 1991, Vol. 148, No. 2, pages 327-335, abstract.	1-6
Y	US 5,653,970 A (VERMEER) 05 August 1997, Entire document.	20-33
Y	US 5,053,222 A (TAKASU et al.) 01 October 1991, entire document.	1-19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but aimed to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 AUGUST 1999

Date of mailing of the international search report

08 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

VICKIE KIM

Telephone No. 703-308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15297

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

CAS ONLINE, MEDLINE, EMBASE, SCISEARCH, EUROPATFUL, DERWENT
search terms: cAMP, cGMP, forskolin, methylxanthine, adenosine triphosphate,
Uncaria Tomentosa, terpene, methylsulfonymethane, etc.